[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 528
1. Sinno H, Thibaudeau S, Coughlin R, Chitte S, Williams B: Management of infantile parotid gland hemangiomas: a 40-year experience. Plast Reconstr Surg; 2010 Jan;125(1):265-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Infantile hemangiomas represent one of the most common childhood tumors.
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Glucocorticoids / therapeutic use. Humans. Infant. Interferons / therapeutic use. Magnetic Resonance Imaging. Neoplasm Regression, Spontaneous. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910858.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 9008-11-1 / Interferons; VB0R961HZT / Prednisone
  • [Number-of-references] 31
  •  go-up   go-down


2. Jaspers GJ, Verkade HJ, Escher JC, de Ridder L, Taminiau JA, Rings EH: Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis; 2006 Sep;12(9):831-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease.
  • 6-Mercaptopurine (6-MP) maintains remission in pediatric Crohn's disease (CD).
  • Azathioprine, a prodrug of 6-MP, is used for maintenance of remission of CD in Europe.
  • We evaluated to what extent azathioprine is used in newly diagnosed pediatric CD patients and whether maintenance of remission differed between patients using azathioprine or not.
  • Active disease was defined as Pediatric Crohn's Disease Activity Index (PCDAI) greater than 10 or systemic corticosteroid use.
  • Remission was defined as PCDAI 10 or less without use of corticosteroids.
  • Median maintenance of first remission in patients who initially used corticosteroids, however, was longer in patients receiving azathioprine compared with nonazathioprine patients (PCDAI, 544 vs. 254 days, P = 0.08; corticosteroid free, 575 vs. 259 days, P < 0.05, respectively).
  • We conclude that, since 2000, azathioprine is being introduced earlier in the treatment of newly diagnosed pediatric CD patients.
  • The use of azathioprine is associated with prolonged maintenance of the first remission.
  • [MeSH-minor] Adolescent. Child. Drug Administration Schedule. Female. Humans. Male. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954801.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] MRK240IY2L / Azathioprine
  •  go-up   go-down


3. Kwinta-Rybicka J, Wilkosz K, Wierzchowska-Słowiacze EK, Ogarek I, Moczulska A, Stec Z, Pełkowska A, Sancewicz-Pach K, Pietrzyk JA: [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report]. Przegl Lek; 2006;63 Suppl 3:44-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
  • The management of nephrotic syndrome (NS) in children remains a clinical challenge for pediatricians and pediatric nephrologists.
  • The aim of this study was to tentatively assess the usefulness and the safety of MMF as an immunosuppressive agent in children with steroid-resistant NS, in whom remission was not obtained with previous treatment regimens, and those with steroid-dependent NS, in whom severe adverse reactions were observed in steroid and cyclosporine therapy.
  • The study included 19 children with NS (11 girls, 8 boys) aged 7 to 19.5 years (a mean of 13.5), treated at the Deptartment of Pediatric Nephrology.
  • [MeSH-minor] Adolescent. Adult. Child. Drug Therapy, Combination. Female. Humans. Male. Remission Induction. Treatment Outcome

  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898486.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunosuppressive Agents; 0 / Steroids; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


Advertisement
4. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK: Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol; 2010 Nov;151(4):295-311
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.
  • Modifications to the treatment of acute lymphoblastic leukaemia (ALL) in children have led to a dramatic increase in survival in the past 40 years.
  • Despite this success, a significant subset of paediatric leukaemia patients either relapse or fail to ever achieve a complete remission.
  • Many novel targeted therapies for the treatment of childhood ALL provide potential mechanisms to further improve cure rates, and provide the possibility of minimizing toxicity to non-malignant cells, given their specificity to malignant cell phenotypes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Molecular Targeted Therapy / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • [Cites] Pediatr Res. 2005 Mar;57(3):430-7 [15659698.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1545-50 [15746059.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):126-37 [15841378.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1049-58 [16038731.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1400-6 [15878982.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3532-7 [16051737.001]
  • [Cites] Cancer Immunol Immunother. 2006 May;55(5):503-14 [16032400.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2643-52 [16352804.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23 [16292537.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2662-9 [16675557.001]
  • [Cites] J Cell Biol. 2006 Jun 19;173(6):833-7 [16769825.001]
  • [Cites] Mol Cancer Ther. 2009 Jul;8(7):1808-17 [19567821.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):505-8 [19418547.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):978-83 [19637330.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2678-87 [19643988.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1243-6 [19838194.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] Cancer Cell. 2009 Nov 6;16(5):401-12 [19878872.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5459-68 [19826124.001]
  • [Cites] Blood. 2007 Jul 15;110(2):678-85 [17395781.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1269-82 [17613754.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1500-9 [17499001.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1043-50 [17640858.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2774-5 [17881645.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9490-500 [17909059.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2240-5 [17657218.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1639-48 [18347165.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41 [19875969.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):307-10 [19856388.001]
  • [Cites] Blood. 2009 Dec 17;114(26):5271-8 [19843886.001]
  • [Cites] Blood. 2009 Dec 24;114(27):5490-8 [19855078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7 [20018760.001]
  • [Cites] Nat Med. 2010 Feb;16(2):205-13 [20072130.001]
  • [Cites] Leukemia. 2010 Feb;24(2):355-70 [20016527.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1425-32 [20007803.001]
  • [Cites] Blood. 2010 Jul 1;115(26):5312-21 [20139093.001]
  • [Cites] Bioconjug Chem. 2009 Aug 19;20(8):1587-94 [19572629.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 28;175(1):134-42 [1998499.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Leuk Res. 1992 Jun-Jul;16(6-7):597-605 [1635378.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2826-34 [1280479.001]
  • [Cites] Clin Exp Immunol. 1992 Dec;90(3):368-75 [1281055.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1025-31 [8427984.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24057-66 [11929866.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Genes Cells. 2002 Nov;7(11):1173-82 [12390251.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8173-7 [12444553.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):819-30 [12755554.001]
  • [Cites] Blood. 2003 Jul 1;102(1):269-75 [12623837.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7638-43 [12794186.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1824-32 [12738674.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4483-93 [14555522.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Leukemia. 2004 Mar;18(3):521-9 [14712291.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4268-75 [14976048.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Toxicol Sci. 2004 Nov;82(1):341-58 [15319485.001]
  • [Cites] Nature. 1984 Aug 16-22;310(5978):583-6 [6087162.001]
  • [Cites] Science. 1987 Jan 2;235(4784):85-8 [3541203.001]
  • [Cites] Nature. 1987 Feb 12-18;325(6105):631-5 [3543692.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):14701-4 [2203759.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18141-4 [10373409.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Adv Exp Med Biol. 1999;457:325-33 [10500808.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Nat Med. 2005 Jan;11(1):71-6 [15619634.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1680-3 [9733516.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27084-90 [9765224.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):680-5 [9892693.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):715-22 [10048973.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1181-9 [18085673.001]
  • [Cites] Blood. 2008 May 15;111(10):5093-100 [18349321.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):34-41 [18260120.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1101-9 [18483299.001]
  • [Cites] J Biol Chem. 2008 Jun 27;283(26):18292-302 [18434310.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):909-15 [8164041.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):292-301 [7575604.001]
  • [Cites] Cell. 1995 Oct 20;83(2):289-99 [7585946.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2870-7 [8639906.001]
  • [Cites] Nature. 1996 Feb 15;379(6566):645-8 [8628398.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] Oncogene. 1996 Dec 19;13(12):2589-94 [9000132.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):43-9 [9422522.001]
  • [Cites] Semin Immunol. 1998 Aug;10(4):287-97 [9695185.001]
  • [Cites] Leukemia. 2000 Mar;14(3):399-402 [10720133.001]
  • [Cites] Blood. 2000 Jul 15;96(2):676-84 [10887134.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Biochemistry. 2001 Jan 30;40(4):1117-23 [11170436.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Cell Death Differ. 2001 Oct;8(10):1014-21 [11598799.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46639-46 [11583996.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(4):685-99 [16997177.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6092-100 [16652142.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):31-40 [16865529.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):327-33 [17080335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1783-8 [17363533.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1789-93 [17363534.001]
  • [Cites] Adv Cancer Res. 2008;100:35-83 [18620092.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2020-3 [18544682.001]
  • [Cites] Cancer. 2008 Sep 1;113(5):985-94 [18615627.001]
  • [Cites] Pathol Oncol Res. 2008 Sep;14(3):275-9 [18575824.001]
  • [Cites] Semin Oncol. 2008 Oct;35(5):484-93 [18929147.001]
  • [Cites] Oncologist. 2008 Nov;13(11):1181-92 [18987046.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):218-21 [18692895.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):886-91 [19455460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Leukemia. 2009 Jul;23(7):1342-3 [19322208.001]
  • (PMID = 20813012.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD000850; United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / R01 CA137078; United States / NCI NIH HHS / CA / 5P50CA058187
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.- / Phosphotransferases
  • [Other-IDs] NLM/ NIHMS374428; NLM/ PMC3354740
  •  go-up   go-down


5. Andersson A, Ritz C, Lindgren D, Edén P, Lassen C, Heldrup J, Olofsson T, Råde J, Fontes M, Porwit-Macdonald A, Behrendtz M, Höglund M, Johansson B, Fioretos T: Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia; 2007 Jun;21(6):1198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status.
  • Gene expression analyses were performed on 121 consecutive childhood leukemias (87 B-lineage acute lymphoblastic leukemias (ALLs), 11 T-cell ALLs and 23 acute myeloid leukemias (AMLs)), investigated during an 8-year period at a single center.
  • In pediatric leukemias with uncharacteristic cytogenetic aberrations or with a normal karyotype, unsupervised analysis identified two novel subgroups: one consisting mainly of cases remaining in complete remission (CR) and one containing a few patients in CR and all but one of the patients who relapsed.
  • This study of a consecutive series of childhood leukemias confirms and extends further previous reports demonstrating that global gene expression profiling provides a valuable tool for genetic and clinical classification of childhood leukemias.
  • [MeSH-major] Leukemia / classification. Leukemia / genetics. Neoplasm, Residual / diagnosis. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Acute Disease. Algorithms. Child. Gene Expression Profiling. Genes, cdc. Humans. Leukemia, B-Cell. Leukemia, Myeloid. Leukemia, T-Cell. Predictive Value of Tests. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410184.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S, Cheng C, Howard SC, Metzger ML, Bhojwani D, Downing JR, Evans WE, Relling MV: Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia; 2010 Feb;24(2):371-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.
  • Factors consistently associated with treatment outcome were age, leukocyte count, immunophenotype, DNA index, and minimal residual disease level after remission induction treatment.
  • Owing to concerns about therapy-related secondary myeloid leukemia and brain tumors, in our current trials we reserve the use of etoposide for patients with refractory or relapsed leukemia undergoing hematopoietic stem cell transplantation, and cranial irradiation for those with CNS relapse.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857425 for PMID:20010620 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3381-4 [11071631.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):184-8 [12525508.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3084-91 [12915598.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):136-42 [2787477.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):61-6 [1670723.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4178-83 [18768390.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):125-34 [19138562.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Leukemia. 2009 Mar;23(3):557-64 [18987654.001]
  • [Cites] Leukemia. 2009 Mar;23(3):528-34 [19020543.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1073-9 [19212338.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1406-9 [19282835.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1682-7 [1944468.001]
  • [Cites] Leukemia. 1992 Feb;6(2):150-7 [1552746.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):314-9 [8321259.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1289-95 [8413409.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1680-4 [7564509.001]
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Mol Pharmacol. 1997 Jul;52(1):155-63 [9224825.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1643-50 [10029593.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Blood. 2006 Jan 15;107(2):843-4 [16401827.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2006 Jul 1;108(1):97-102 [16537802.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] JAMA. 2007 Mar 21;297(11):1207-15 [17374815.001]
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Leukemia. 2008 May;22(5):989-97 [18305563.001]
  • (PMID = 20010620.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NIGMS NIH HHS / GM / U01 GM061393-06; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401-19; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA36401; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA78224; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NIGMS NIH HHS / GM / GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / R01 CA078224-09; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; United States / NCI NIH HHS / CA / CA51001; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS137362; NLM/ PMC2820159
  •  go-up   go-down


7. Vivarelli M, Moscaritolo E, Tsalkidis A, Massella L, Emma F: Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J Pediatr; 2010 Jun;156(6):965-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify early prognostic factors for idiopathic nephrotic syndrome (INS) in childhood.
  • A significant association was found between the interval from onset of steroid therapy to remission and the risk of relapsing within 3 months after steroid therapy discontinuation (P < .0001).
  • A similar association was found between the time to achieve remission and the risk of developing frequent relapsing or steroid-dependent nephrotic syndrome (P < .0001), the prescription of maintenance steroid therapy (P < .003), and the prescription of all other non-steroid drugs (P < .0001) during follow-up.
  • Patients with non-relapsing and infrequent relapsing nephrotic syndrome had a median time to achieve remission <7 days; in patients with frequent relapsing and steroid-dependent nephrotic syndrome, this median was >7 days.
  • CONCLUSION: The interval from onset of steroid therapy to remission is an accurate early prognostic factor in INS.
  • [MeSH-minor] Cyclosporine / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Prognosis. ROC Curve. Remission Induction. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20223477.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; VB0R961HZT / Prednisone
  •  go-up   go-down


8. Visudtibhan A, Thampratankul L, Khongkhatithum C, Okascharoen C, Siripornpanich V, Chiemchanya S, Visudhiphan P: Migraine in junior high-school students: A prospective 3-academic-year cohort study. Brain Dev; 2010 Nov;32(10):855-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Migraine is a common childhood illness with expected favorable outcome.
  • A study of the long-term clinical course of childhood migraine will provide information of evolution of migraine.
  • Spontaneous remission and avoidance of precipitating causes contributed to relief of migraine in the majority of the students.

  • Genetic Alliance. consumer health - Migraine.
  • MedlinePlus Health Information. consumer health - Migraine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier B.V. All rights reserved.
  • [CommentIn] Brain Dev. 2011 Jan;33(1):90 [20356694.001]
  • (PMID = 20060252.001).
  • [ISSN] 1872-7131
  • [Journal-full-title] Brain & development
  • [ISO-abbreviation] Brain Dev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Bhojwani D, Howard SC, Pui CH: High-risk childhood acute lymphoblastic leukemia. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S222-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-risk childhood acute lymphoblastic leukemia.
  • Although most children with acute lymphoblastic leukemia (ALL) are cured, certain subsets have a high risk of relapse.
  • Infants with mixed-lineage leukemia (MLL)-rearranged ALL comprise a very poor-risk group wherein further intensification of chemotherapy causes significant toxicity.
  • Hybrid protocols incorporating drugs effective for acute myeloid leukemia could improve survival, a strategy being tested in international trials.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Glucocorticoids / therapeutic use. Humans. Infant. Neoplasm, Residual / drug therapy. Polymerase Chain Reaction. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Mar 15;111(6):2984-90 [18182569.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1496-503 [18349402.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Blood. 2008 May 1;111(9):4477-89 [18285545.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S71-4 [18545248.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4027-31 [18593977.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3204-12 [18541900.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4392-9 [18628453.001]
  • [Cites] Haematologica. 2008 Aug;93(8):1155-60 [18519521.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1005-12 [18477770.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4376-84 [18802149.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4318-27 [18723429.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):39-51 [19100367.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):100-6 [19100372.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] Blood. 2006 Jul 1;108(1):97-102 [16537802.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5742-9 [17179108.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):16-24 [17194902.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):218-27 [17241927.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2327-30 [17095619.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Lancet. 2007 Jun 9;369(9577):1947-54 [17560447.001]
  • [Cites] Blood. 2007 Jul 15;110(2):727-34 [17405907.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):240-50 [17658395.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1112-5 [17473063.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4813-20 [17947730.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2258-63 [17690691.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):823-33 [17957188.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):445-53 [12406084.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(10):909-18 [12748668.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2736-40 [12843002.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):8-23 [14752789.001]
  • [Cites] Leukemia. 2004 Mar;18(3):521-9 [14712291.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Nat Genet. 2004 May;36(5):453-61 [15098032.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Clin Oncol. 1985 Nov;3(11):1513-21 [3863894.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):527-35 [9469337.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):2030-9 [9806664.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1221-6 [10450750.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1485-9 [15784872.001]
  • [Cites] Blood. 2005 May 1;105(9):3749-56 [15637143.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):635-42 [16112299.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2484-90 [15956279.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):999-1005 [16338622.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Leukemia. 2006 Feb;20(2):264-71 [16357833.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):283-9 [18182669.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):352-9 [18223208.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2008 Mar;38(3):78-94 [18279790.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):257-68 [18308251.001]
  • (PMID = 19778845.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids
  • [Number-of-references] 92
  • [Other-IDs] NLM/ NIHMS163517; NLM/ PMC2814411
  •  go-up   go-down


10. Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R, Nordic Society for Paediatric Haematology and Oncology: Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood; 2009 Jun 11;113(24):6077-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
  • Among 1614 children with acute lymphoblastic leukemia (ALL) treated with the Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL-92 protocol, 20 patients developed a second malignant neoplasm (SMN) with a cumulative risk of 1.6% at 12 years from the diagnosis of ALL.
  • Nine of the 16 acute myeloid leukemias or myelodysplastic syndromes had monosomy 7 (n = 7) or 7q deletions (n = 2).
  • This study indicates that the duration and intensity of 6MP/MTX maintenance therapy of childhood ALL may influence the risk of SMNs in childhood ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 1184168600 for PMID:19224761 [PharmGKB] .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1332-9 [12663723.001]
  • [Cites] Br J Clin Pharmacol. 2001 Nov;52(5):539-46 [11736862.001]
  • [Cites] Eur J Haematol. 2003 Jun;70(6):363-72 [12756018.001]
  • [Cites] Leukemia. 2003 Jul;17(7):1344-8 [12835723.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2540-2 [14523457.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2177-84 [12399959.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1670-4 [7712473.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1680-4 [7564509.001]
  • [Cites] Science. 1996 Aug 23;273(5278):1109-11 [8688098.001]
  • [Cites] Am J Clin Pathol. 1996 Nov;106(5):676-9 [8929481.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10338-43 [11526240.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Clin Chim Acta. 1978 May 2;85(3):323-33 [657528.001]
  • [Cites] Drug Metab Rev. 1985;16(1-2):157-74 [3905317.001]
  • [Cites] Adv Exp Med Biol. 1986;195 Pt B:135-9 [2429504.001]
  • [Cites] Blood. 1990 Jan 1;75(1):166-73 [1688495.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1682-7 [1944468.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Eur J Clin Pharmacol. 1992;43(4):329-39 [1451710.001]
  • [Cites] Biochemistry. 1997 Mar 4;36(9):2501-6 [9054555.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):600-12 [9452280.001]
  • [Cites] Acta Paediatr. 1998 Jan;87(1):108-11 [9510461.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(4):266-72 [9744770.001]
  • [Cites] Acta Paediatr. 1998 Nov;87(11):1151-61 [9846917.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1080-6 [10491537.001]
  • [Cites] Lancet. 1999 Sep 25;354(9184):1126-7 [10509534.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):878-82 [16041371.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1629-38 [16550163.001]
  • [Cites] Neurobiol Aging. 2006 May;27(5):710-6 [16005550.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1955-62 [16990760.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] JAMA. 2007 Mar 21;297(11):1207-15 [17374815.001]
  • [Cites] J Natl Cancer Inst. 2007 May 16;99(10):790-800 [17505074.001]
  • [Cites] Pediatr Blood Cancer. 2007 Sep;49(3):294-7 [17243137.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2128-36 [17673902.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1581-2 [18024413.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):24-36 [18097462.001]
  • [Cites] Am J Hematol. 2008 Jan;83(1):80-3 [17696202.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Mar 15;864(1-2):149-55 [18313997.001]
  • [Cites] Blood. 2008 May 1;111(9):4477-89 [18285545.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):831-49 [18989161.001]
  • [Cites] Leukemia. 2009 Mar;23(3):557-64 [18987654.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Leukemia. 2000 Feb;14(2):232-7 [10673738.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):319-27 [10797353.001]
  • [Cites] Cancer Treat Rev. 2000 Oct;26(5):377-91 [11006138.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):672-8 [11058888.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2193-4 [11187910.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Leukemia. 2001 Jan;15(1):74-9 [11243403.001]
  • [CommentIn] Blood. 2009 Jun 11;113(24):6258; author reply 6258-9 [19520817.001]
  • [CommentIn] Blood. 2009 Jun 11;113(24):6041-2 [19520809.001]
  • (PMID = 19224761.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM028157; United States / NIGMS NIH HHS / GM / U01 GM061388; United States / NIGMS NIH HHS / GM / R01-GM28157; United States / NIGMS NIH HHS / GM / U01 GM61388
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2699230
  • [Investigator] Schmiegelow K; Hejl M; Østergård M; Schrøder H; Pihkala U; Ilanmaa E; Antila K; Korpela K; Vuorinen O; Perkkiö M; Kojo N; Nyman R; Pere M; Lanning M; Niemi A; Vuoristo A; Niemi S; Isotalo J; Laapas H; Mäkipernaa A; Salmi T; Varsamäki T; Kristinsson J; Zeller B; Danielsen O; Madsen B; Nielsen B; Stensvold K; Lund JH; Danielsen K; Brekke P; Stamnes O; Glomstein A; Widing E; Hapnes C; Stokland T; Kolmannskog S; Halvorsen B; Spangen S; Carlsson G; Bergkvist M; Skanka N; Korlén B; Dimberg A; Adrian BA; Mellander L; Aronson S; Jensen D; Winiarski J; Lagerwall A; Jonsson NO; Cervin T; Samuelsson U; Berg A; Nilsson H; Behrendtz M; Wiebe T; Ljung R; Tessin I; Ljungren CG; Dohlwitz A; Christensen HO; Ronge E; Berglund M; Björk O; Fransson D; Eriksson M; Forestier E; Kreuger A; Blomgren M; Rönnblad B; Eriksson B; Berg T; Hedling L; Forsberg T; Lindquist B; Kriström B; Hjalmars U
  •  go-up   go-down


11. Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, Pullen J, Pettenati MJ, Carroll AJ, Shuster JJ, Camitta B: Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood; 2007 Aug 15;110(4):1105-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
  • Pediatric Oncology Group (POG) protocol 9201 enrolled children with lesser-risk B-lineage acute lymphoblastic leukemia (ALL) defined by age (1-9), white blood cell count (WBC) less than 50 x 10(9)/L (50,000/microL), DNA findings of trisomies 4 and 10 (or DNA index > 1.16), and lack of overt central nervous system (CNS) leukemia.
  • After vincristine, prednisone, and asparaginase induction, 650 of 653 eligible patients attained remission (3 induction deaths) and received 6 courses of intravenous methotrexate (1 g/m(2)) with daily mercaptopurine.


12. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG): Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. Br J Haematol; 2009 May;145(3):376-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.
  • Anthracyclines are used to treat childhood acute lymphoblastic leukaemia (ALL) but non-randomized studies suggest that cardiotoxicity may be a problem.
  • Individual patient data from trials in childhood ALL that randomized anthracyclines or methods of reducing cardiotoxicity were analysed by standard meta-analysis methods.
  • However there was a non-significant increase in induction failures, and in deaths in first remission.
  • Anthracyclines are effective against bone marrow relapse but have not been shown to significantly increase event free survival in childhood ALL.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cardiotonic Agents / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Heart Diseases / chemically induced. Humans. Infant. Male. Odds Ratio. Randomized Controlled Trials as Topic. Remission Induction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14 [16781284.001]
  • [Cites] Semin Oncol. 2006 Jun;33(3 Suppl 8):S2-7 [16781283.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005008 [17054232.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3191-8 [16987655.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):226-30 [17242696.001]
  • [Cites] Klin Padiatr. 2007 May-Jun;219(3):134-8 [17525906.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1106-11 [18309945.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1444-54 [11230490.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):25-36 [11815957.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):503-12 [12056699.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1767-72 [12365026.001]
  • [Cites] Am J Hematol. 2002 Dec;71(4):241-7 [12447951.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):145-53 [15247354.001]
  • [Cites] Cancer. 1974 Feb;33(2):545-54 [4521474.001]
  • [Cites] Ned Tijdschr Geneeskd. 1975 Sep 20;119(38):1445-51 [1101081.001]
  • [Cites] Cancer. 1976 Mar;37(3):1243-7 [1063049.001]
  • [Cites] Med Pediatr Oncol. 1977;3(3):281-7 [284168.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Summer;11(2):125-33 [2665546.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):187-96 [2064956.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3120-30 [8221579.001]
  • [Cites] Mol Aspects Med. 1994;15 Suppl:s207-12 [7752832.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(1):CD003917 [15674919.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005006 [17054231.001]
  • (PMID = 19236609.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / U10 CA029139-22; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Cardiotonic Agents
  • [Number-of-references] 29
  • [Other-IDs] NLM/ NIHMS163765; NLM/ PMC2812732
  • [Investigator] Yetgin S; Obek NY; Masera G; Valsecchi MG; Dacou-Voutetakis; Loening L; Schrappe M; Zimmermann M; Henze G; von Stackelberg A; Gadner H; Mann G; Attarbaschi A; Brandalise SR; Carroll WL; Gaynon P; Boyett JM; Nachman J; Devidas M; Sather HN; Escherich G; Janka G; Gelber RD; Sallan SE; Pieters R; Bierings M; Kamps WA; Otten J; Suciu S; Viana MB; Baruchel A; Auclerc M; Perez C; Solidaro A; Stark B; Steinberg D; Koizumi S; Tsurusawa M; Zintl F; Schiller I; Matsuzaki A; Eden TO; Lilleyman JS; Richards S; Steinherz PG; Steinherz L; Kochupillai V; Bakhshi S; Ortega JJ; Nachman J; Appelbaum FR; Cheng C; Pei D; Pui CH; Kukure P; Nakazawa S; Tsuchida M; Elphinstone T; Evans V; Gettins L; Hicks C; MacKinnon L; Morris P; Richards S; Wade R
  •  go-up   go-down


13. Liang XL, Xian Y, Dai BT, Xu YH, Su YC, Wang SY, Lu LL, Li X, Yu J: [Clinical study on childhood acute lymphoblastic leukemia diagnosed and treated with 04 Protocol in Chongqing, China]. Zhonghua Er Ke Za Zhi; 2009 Dec;47(12):939-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on childhood acute lymphoblastic leukemia diagnosed and treated with 04 Protocol in Chongqing, China].
  • OBJECTIVE: To analyze the clinical and laboratory data from acute lymphoblastic leukemia (ALL) patients and the results of treatment using 04 Protocol (suggested by the Pediatric Hematology Group of Chinese Medical Association in 2004).
  • RESULTS: From October 2004 to June 2007, 88 childhood ALL patients were treated with the 04 Protocol.
  • Sixty-three (91.30%) patients attained complete remission (CR) and 17 patients lost to follow up.
  • Clinical risk classification and the leukemia cells of D19 are independent predictors of prognosis of ALL.
  • High dose methotrexate played an important role in prevention and treatment of central nervous system leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


14. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol; 2010 Oct;5(10):1844-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most childhood cases are caused by Shiga toxin-producing bacteria.
  • Plasma therapy induced remission in 55 to 80% of episodes in patients with CFH, C3, or THBD mutations or autoantibodies, whereas patients with CFI (factor I) mutations were poor responders. aHUS recurred frequently after kidney transplantation except for patients with MCP mutations.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2008 Apr 15;85(7):923-7 [18408568.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1512-4 [18006700.001]
  • [Cites] Am J Transplant. 2008 Aug;8(8):1694-701 [18557729.001]
  • [Cites] Pediatr Nephrol. 2008 Oct;23(10):1749-60 [18704506.001]
  • [Cites] Pediatr Nephrol. 2008 Nov;23(11):1957-72 [18594873.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4948-52 [18796626.001]
  • [Cites] J Immunol. 2009 Jan 15;182(2):1061-8 [19124749.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Jan;4(1):201-6 [19005013.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):542-4 [19179328.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):544-6 [19179329.001]
  • [Cites] Thromb Haemost. 2009 Feb;101(2):227-32 [19190803.001]
  • [Cites] Thromb Haemost. 2009 Feb;101(2):271-8 [19190809.001]
  • [Cites] Pediatr Nephrol. 2009 Apr;24(4):687-96 [18800230.001]
  • [Cites] J Am Soc Nephrol. 2009 Mar;20(3):524-34 [19176699.001]
  • [Cites] J Am Soc Nephrol. 2009 May;20(5):940-9 [19092117.001]
  • [Cites] J Med Genet. 2009 Jul;46(7):447-50 [19435718.001]
  • [Cites] N Engl J Med. 2009 Jul 23;361(4):345-57 [19625716.001]
  • [Cites] Pediatr Nephrol. 2009 Sep;24(9):1757-60 [19373492.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Aug;4(8):1312-6 [19556379.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Aug;4(8):1356-62 [19590060.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2837-45 [19584399.001]
  • [Cites] Nephrol Dial Transplant. 2009 Nov;24(11):3548-51 [19633317.001]
  • [Cites] Am J Transplant. 2009 Nov;9(11):2644-5 [19775316.001]
  • [Cites] N Engl J Med. 2009 Oct 22;361(17):1676-87 [19846853.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4261-71 [19745068.001]
  • [Cites] Blood. 2010 Jan 14;115(2):379-87 [19861685.001]
  • [Cites] Kidney Int. 2010 Feb;77(4):339-49 [20016463.001]
  • [Cites] Am J Kidney Dis. 2010 Apr;55(4):708-11 [19854549.001]
  • [Cites] Kidney Int. 2001 Sep;60(3):831-46 [11532079.001]
  • [Cites] Lancet. 2002 May 11;359(9318):1671-2 [12020532.001]
  • [Cites] Hum Mol Genet. 2003 Dec 15;12(24):3385-95 [14583443.001]
  • [Cites] Am J Kidney Dis. 2004 Jun;43(6):976-82 [15168377.001]
  • [Cites] Arteriosclerosis. 1989 Nov-Dec;9(6):802-11 [2480105.001]
  • [Cites] Ren Fail. 1998 Nov;20(6):845-50 [9834983.001]
  • [Cites] J Am Soc Nephrol. 2005 Feb;16(2):555-63 [15590760.001]
  • [Cites] Am J Kidney Dis. 2005 Jan;45(1):e12-5 [15696434.001]
  • [Cites] Am J Transplant. 2005 May;5(5):1146-50 [15816899.001]
  • [Cites] Mol Immunol. 2006 Jan;43(1-2):68-77 [16023727.001]
  • [Cites] J Am Soc Nephrol. 2006 Jan;17(1):170-7 [16338962.001]
  • [Cites] Kidney Int. 2006 Aug;70(3):423-31 [16775594.001]
  • [Cites] Am J Transplant. 2006 Aug;6(8):1948-52 [16889549.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1267-79 [16621965.001]
  • [Cites] PLoS Med. 2006 Oct;3(10):e431 [17076561.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):240-5 [17182750.001]
  • [Cites] J Am Soc Nephrol. 2007 Aug;18(8):2392-400 [17599974.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Jan;1(1):88-99 [17699195.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2007 Nov;16(6):565-71 [18089972.001]
  • [Cites] Pediatr Nephrol. 2008 Sep;23(9):1517-21 [18483746.001]
  • (PMID = 20595690.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP07193; United Kingdom / Medical Research Council / / G0701325
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD46; 0 / Autoantibodies; 0 / C3 protein, human; 0 / CD46 protein, human; 0 / Complement C3; 0 / THBD protein, human; 0 / Thrombomodulin; 0 / complement factor H, human; 80295-65-4 / Complement Factor H; 9007-36-7 / Complement System Proteins
  • [Other-IDs] NLM/ PMC2974386
  •  go-up   go-down


15. Khalid S, Moiz B, Adil SN, Khurshid M: Retrospective review of pediatric patients with acute lymphoblastic leukemia: a single center experience. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):704-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of pediatric patients with acute lymphoblastic leukemia: a single center experience.
  • OBJECTIVE: We reviewed the clinical details and treatment outcome of children with newly diagnosed acute lymphoblastic leukemia (ALL) to determine the significance of already established prognostic factors in our patients.
  • Forty five (97.8%) of these were in complete remission after 28 days of induction therapy.
  • CONCLUSION: We found that ALL is a frequent childhood hematological malignancy in our setting and is more prevalent in males and children less than ten years of age.
  • Age and leukemia phenotype emerged as the important prognostic factors in pediatric ALL in our patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045397.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


16. Kaste SC, Howard SC, McCarville EB, Krasin MJ, Kogos PG, Hudson MM: 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol; 2005 Feb;35(2):141-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's.
  • About 1,700 children in the United States are diagnosed yearly with lymphomas; Hodgkin's disease accounts for approximately half of these cases, or 6% of all childhood cancers.
  • Contemporary therapy allows for the achievement of remission in the majority of cases.
  • However, experience with 18F-FDG PET-CT is limited in pediatric Hodgkin's disease.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2003 Sep;124(3):893-901 [12970014.001]
  • [Cites] Drugs. 1991 Aug;42(2):300-30 [1717226.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23 (2):315-40; quiz 533 [12640150.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):173-80 [9440740.001]
  • [Cites] AJR Am J Roentgenol. 2002 Nov;179(5):1337-43 [12388526.001]
  • [Cites] Am J Clin Pathol. 1990 Feb;93(2):219-26 [2405631.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):266-71 [14960646.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3755-7 [12228193.001]
  • [Cites] Radiology. 1995 Sep;196 (3):851-5 [7644655.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1789-96 [14602861.001]
  • [Cites] Pediatr Radiol. 2004 Mar;34(3):205-13 [14745525.001]
  • [Cites] Pediatr Radiol. 2004 Mar;34(3):214-21 [14745527.001]
  • [Cites] Pediatr Radiol. 2004 Mar;34(3):190-8 [14745528.001]
  • [Cites] Radiology. 1998 Nov;209(2):471-5 [9807576.001]
  • [Cites] Clin Positron Imaging. 2000 Jul;3(4):176 [11150779.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S117-27 [12748831.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2478-80 [1933785.001]
  • [Cites] J Nucl Med. 1996 Jul;37(7):1127-9 [8965182.001]
  • (PMID = 15654605.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 21
  •  go-up   go-down


17. Zaliova M, Fronkova E, Krejcikova K, Muzikova K, Mejstrikova E, Stary J, Trka J, Zuna J: Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring. Leukemia; 2009 May;23(5):944-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimal residual disease (MRD) monitoring is an essential tool for risk group stratification in current treatment protocols for childhood acute lymphoblastic leukaemia (ALL).
  • We conclude that BCR/ABL-based MRD monitoring of childhood ALL is a clinically relevant tool and should be performed in parallel with the standard Ig/TCR follow-up.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Neoplasm Recurrence, Local / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Cells, Cultured. Child. Child, Preschool. Female. Gene Rearrangement, T-Lymphocyte / genetics. Genes, Immunoglobulin / genetics. Humans. Male. Neoplasm, Residual / genetics. Precursor Cells, B-Lymphoid / metabolism. Precursor Cells, B-Lymphoid / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19158828.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


18. Bader-Meunier B, Aladjidi N, Bellmann F, Monpoux F, Nelken B, Robert A, Armari-Alla C, Picard C, Ledeist F, Munzer M, Yacouben K, Bertrand Y, Pariente A, Chaussé A, Perel Y, Leverger G: Rituximab therapy for childhood Evans syndrome. Haematologica; 2007 Dec;92(12):1691-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy for childhood Evans syndrome.
  • Complete or partial remission of at least one cytopenia was achieved in 13 out of the 17 patients (76%), and lasted in 11 of them with a mean follow-up of 2.4 years (range 0.5-7 years).
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Murine-Derived. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. France. Humans. Infant. Infection / chemically induced. Infection / mortality. Male. Prednisolone / administration & dosage. Prednisolone / adverse effects. Registries. Remission Induction. Rituximab. Survival Rate. Syndrome

  • Genetic Alliance. consumer health - Evans Syndrome.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2007 Dec;92(12):1589-96 [18055980.001]
  • (PMID = 18055994.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


19. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet; 2007 Jul 21;370(9583):240-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
  • BACKGROUND: Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children.
  • We initiated an international study to investigate the effects of a new hybrid treatment protocol with elements designed to treat both acute lymphoblastic leukaemia and acute myeloid leukaemia, and to identify any prognostic factors for outcome in infants.
  • Eligible patients were stratified for risk according to their peripheral blood response to a 7-day prednisone prophase, and then given a hybrid regimen based on the standard protocol for acute lymphoblastic leukaemia, with some elements designed for treatment of acute myeloid leukaemia.
  • Before the maintenance phase, a subset of patients in complete remission were randomly assigned to receive either standard treatment or a more intensive chemotherapy course with high-dose cytarabine and methotrexate.
  • FINDINGS: In the 482 enrolled patients who underwent hybrid treatment, 260 (58%) were in complete remission at a median follow-up of 38 (range 1-78) months, and EFS at 4 years was 47.0% (SE 2.6, 95% CI 41.9-52.1).
  • Of 445 patients in complete remission after 5 weeks of induction treatment, 191 were randomised: 95 patients to receive a late intensification course, and 96 to a control group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2007 Jul 21;370(9583):198-200 [17658376.001]
  • (PMID = 17658395.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00015873; ISRCTN/ ISRCTN24251487
  • [Grant] United Kingdom / Medical Research Council / / G0300130
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


20. Mussolin L, Pillon M, Conter V, Piglione M, Lo Nigro L, Pierani P, Micalizzi C, Buffardi S, Basso G, Zanesco L, Rosolen A: Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood. J Clin Oncol; 2007 Nov 20;25(33):5254-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
  • PURPOSE: To study the prevalence of t(8;14) at diagnosis and the response kinetics to treatment of minimal residual disease (MRD) in B-cell acute lymphoblastic leukemia (B-ALL) patients and determine its impact on prognosis.
  • PATIENTS AND METHODS: A total of 68 children affected by de novo B-ALL enrolled onto the Berlin-Frankfurt-Muenster-based Italian Association of Pediatric Hematology and Oncology LNH-97 clinical protocol were studied.
  • All of them reached clinical complete remission and most (31 of 39) became MRD negative after the first chemotherapy cycle.
  • The 3-year relapse-free survival (RFS) was 38% (SE = 17%) in patients MRD positive after the first chemotherapy cycle compared with 84% (SE = 7%) in MRD-negative patients (P = .0005), whereas there was no difference in RFS for children who reached a clinical complete remission after the first chemotherapy cycle versus those who did not (RFS = 72% and SE = 9%; RFS = 79% and SE = 11%, respectively; P = .8).
  • [MeSH-major] Burkitt Lymphoma / mortality. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024872.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


21. Satwani P, Sather H, Ozkaynak F, Heerema NA, Schultz KR, Sanders J, Kersey J, Davenport V, Trigg M, Cairo MS: Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report. Biol Blood Marrow Transplant; 2007 Feb;13(2):218-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.
  • The prognosis for childhood acute lymphoblastic leukemia (ALL) has improved dramatically over the past quarter of a century.
  • Despite improvements in the treatment of childhood ALL, relapse still occurs in 20%-30% of patients.
  • Children (2 months to 21 years) with > or =1 ultra-high-risk feature (UHRF) of ALL in first remission treated on a frontline Children's Cancer Group (CCG) ALL study with a matched family allogeneic donor were eligible for study entry onto CCG-1921 and an allogeneic bone marrow transplant (AlloBMT).
  • Twenty-nine patients with a median age of 8.7 years with UHRF ALL in first complete remission (CR1) received an AlloBMT from a family member.
  • The incidence of grade II-IV acute GVHD was 20.7% and the incidence of chronic GVHD was 3.7%.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Dec;13(12):2053-8 [10602428.001]
  • [Cites] Blood. 1991 Feb 1;77(3):435-9 [1991160.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2412-8 [11001892.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Leuk Res. 1986;10(4):457-9 [3515055.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):657-63 [2943992.001]
  • [Cites] Blood. 1991 Oct 15;78(8):1923-7 [1912575.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):97-100 [1554802.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • [Cites] Blood. 1992 Aug 15;80(4):1090-3 [1498326.001]
  • [Cites] Lancet. 1992 Sep 5;340(8819):565-8 [1355153.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1289-95 [8413409.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1275-9 [8057661.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1395-404 [10189148.001]
  • [Cites] Br J Haematol. 2005 Apr;129(1):35-44 [15801953.001]
  • [Cites] Blood. 2005 May 1;105(9):3749-56 [15637143.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):635-42 [16112299.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):999-1005 [16338622.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Blood. 2006 Jul 15;108(2):441-51 [16556894.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):535-8 [7537528.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3353-4 [7756668.001]
  • [Cites] Bone Marrow Transplant. 1995 Nov;16(5):663-7 [8547863.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):357-63 [8704687.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):365-9 [8704688.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):35-42 [9065717.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1410-4 [9269758.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4243-51 [9373234.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2285-95 [9404706.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1031-6 [9665186.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2730-41 [9763557.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(11):1029-33 [9877263.001]
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):1-6 [9917745.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):445-55 [10080584.001]
  • [Cites] Blood. 1987 Aug;70(2):587-8 [3300815.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):747-53 [2654331.001]
  • [Cites] Blood. 1990 Aug 1;76(3):489-94 [2378982.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):340-7 [10637248.001]
  • (PMID = 17241927.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA013539; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA 13539; United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS17434; NLM/ PMC2731715
  •  go-up   go-down


22. Obidike EO: Concurrent use of cyclophosphamide and prednisolone in childhood nephrotic syndrome in South-East Nigeria; a report of 5 cases. Niger J Clin Pract; 2009 Mar;12(1):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent use of cyclophosphamide and prednisolone in childhood nephrotic syndrome in South-East Nigeria; a report of 5 cases.
  • RESULTS: Five cases were treated and all have been in clinical remission for more than 4 years as at the time of the review, though 2 of them relapsed twice initially.
  • CONCLUSION: This treatment protocol appears beneficial to childhood nephrotics in this environment and should be used.

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562934.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


23. Pan C, Gu LJ, Xue HL, Chen J, Dong L, Zhou M, Luo CY, Wang YP, Tang JY: [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].
  • OBJECTIVE: To improve the treatment outcome of children with acute lymphoblastic leukemia (ALL), and to evaluate the efficacy and safety of a modified induction chemotherapy between the two protocols used to treat children with ALL in Shanghai Children's Medical Center.
  • 1st, 2006, 311 patients with newly diagnosed childhood ALL, who underwent induction chemotherapy for over 10 days, were eligible for analysis.
  • Clinically, the distributions of the initial data from the patients, treatment responses, complete remission rates after therapy, and treatment-associated infections in the two groups were evaluated.
  • RESULTS: Patients from the two groups obtained similar complete remission rate (91.8% vs. 95.6%, P = 0.29), while patients from Group 05 were benefited more from their therapy.
  • Patients in the Group 05 also had shortened period from the beginning day of the initial therapy to complete remission (32.34 +/- 3.36 days vs. 34.18 +/- 4.96 days, P < 0.01).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphoid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697614.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


24. Carret AS, Tabori U, Crooks B, Hukin J, Odame I, Johnston DL, Keene DL, Freeman C, Bouffet E, Canadian Pediatric Brain Tumour Consortium: Outcome of secondary high-grade glioma in children previously treated for a malignant condition: a study of the Canadian Pediatric Brain Tumour Consortium. Radiother Oncol; 2006 Oct;81(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of secondary high-grade glioma in children previously treated for a malignant condition: a study of the Canadian Pediatric Brain Tumour Consortium.
  • BACKGROUND AND PURPOSE: Reports of secondary high-grade glioma (HGG) in survivors of childhood cancer are scarce.
  • The aim of this study was to review the pattern of diagnosis, the treatment, and outcome of secondary pediatric HGG.
  • PATIENTS AND METHODS: We performed a multi-center retrospective study among the 17 paediatric institutions participating in the Canadian Pediatric Brain Tumour Consortium (CPBTC).
  • RESULTS: We report on 18 patients (14 males, 4 females) treated in childhood for a primary cancer, who subsequently developed a HGG as a second malignancy.
  • All patients had previously received radiation therapy +/- chemotherapy for either acute lymphoblastic leukaemia (n=9) or solid tumour (n=9).
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / mortality. Astrocytoma / therapy. Canada. Child. Female. Humans. Male. Neoplasms / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Remission Induction. Retrospective Studies. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16973227.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


25. Patel AM, Lehman TJ: Rituximab for severe refractory pediatric Wegener granulomatosis. J Clin Rheumatol; 2008 Oct;14(5):278-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab for severe refractory pediatric Wegener granulomatosis.
  • We describe a case of pediatric Wegener granulomatosis initially treated with cyclophosphamide and oral corticosteroids resulting in remission for 5 years.
  • Patient achieved remission with rituximab infusion therapy.
  • This demonstrates how rituximab may be beneficial for childhood-onset Wegener granulomatosis unresponsive to conventional therapy.

  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824926.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


26. Cogulu O, Kosova B, Gunduz C, Karaca E, Aksoylar S, Erbay A, Karapinar D, Vergin C, Vural F, Tombuloglu M, Cetingul N, Ozkinay F: The evaluation of hTERT mRNA expression in acute leukemia children and 2 years follow-up of 40 cases. Int J Hematol; 2008 Apr;87(3):276-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evaluation of hTERT mRNA expression in acute leukemia children and 2 years follow-up of 40 cases.
  • The aim of this study is to evaluate (1) the human telomerase-specific reverse transcriptase (hTERT) mRNA expression in childhood acute leukemia, (2) the association between the hTERT mRNA expression with the patients' characteristics and the known prognostic factors and (3) the correlation of the patients' survival with the initial hTERT mRNA value at diagnosis.
  • A total of 40 newly diagnosed patients consist of children [31 cases with acute lymphoblastic leukemia (ALL) and 9 cases with acute myeloblastic leukemia (AML)] were prospectively included into the study.
  • No significant difference was determined between the rate of complete remission and relapse of cases with the hTERT mRNA values in all malignancy groups.
  • In conclusion, the hTERT mRNA expression values were not significantly associated with the known prognostic factors in children both with ALL and AML. hTERT mRNA value is a significant factor for childhood ALL at diagnosis in relation to the estimated survival.
  • [MeSH-major] Biomarkers, Tumor / genetics. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Messenger / metabolism. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2007 May;21(5):965-72 [17344921.001]
  • [Cites] Cancer. 2003 May 1;97(9):2212-7 [12712473.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):1-16 [10963374.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1476-80 [15367406.001]
  • [Cites] Turk J Haematol. 2006 Jun 5;23(2):77-83 [27265287.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4918-22 [9810000.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1003-7 [9545415.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1853-61 [17510216.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):707-11 [15158092.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):393-9 [15621829.001]
  • [Cites] Biochem Soc Trans. 2000 Feb;28(2):245-50 [10816136.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):799-803 [9816233.001]
  • [Cites] Br J Haematol. 1998 Jan;100(1):156-65 [9450805.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1367-75 [9753073.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2001 Nov;22(11):592-4 [11855149.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jan;41(1):29-40 [11796230.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2003 Jul;34(3):486-8 [12910697.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jun;26(6):342-50 [15167346.001]
  • [Cites] Am J Hematol. 2005 Aug;79(4):267-73 [16044449.001]
  • [Cites] Blood. 1995 May 1;85(9):2315-20 [7727765.001]
  • [Cites] Hum Genet. 1998 Apr;102(4):397-402 [9600234.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):619-25 [9815729.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2477-80 [15621763.001]
  • (PMID = 18293058.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


27. Tang JY, Xue HL, Gu LJ, Chen J, Pan C, Chen J, Wang YP, Ye H, Dong L, Zou JY: [Failure of treatment and protocol compliance in patients with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2005 Jul;43(7):490-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Failure of treatment and protocol compliance in patients with acute lymphoblastic leukemia].
  • OBJECTIVE: To analyze the main reason of failure in treatment and compliance to protocol in children with acute lymphoblastic leukemia (ALL) at a single institute which is located at the most developed city of China.
  • The patients who had not received any therapy after ALL diagnosis were accounted as early protocol compliance failure, those who received therapy for less than 15 days were regarded as interim failure in protocol compliance, and those who gave up therapy or were lost in follow-up after 15 days with stable disease or complete remission (CR) were accounted as late compliance failure.
  • CONCLUSION: Protocol compliance failure is the reason as important as the treatment failure for childhood ALL management failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Patient Compliance. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. China. Female. Follow-Up Studies. Humans. Infant. Male. Medication Adherence / statistics & numerical data. Prognosis. Registries. Remission Induction / methods. Risk Factors. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083545.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Pereira TM, Vieira AP, Fernandes JC, Sousa-Basto A: Cyclosporin A treatment in severe childhood psoriasis. J Eur Acad Dermatol Venereol; 2006 Jul;20(6):651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporin A treatment in severe childhood psoriasis.
  • Though used occasionally, systemic therapies in severe childhood psoriasis have not been systematically investigated.
  • Cyclosporin A (CysA) is effective in adults with severe psoriasis but there are no extensive data regarding the efficacy and safety of its use in childhood psoriasis.
  • Improvement of skin lesions was achieved after between 4 and 30 (mean: 12) weeks of treatment, with complete remission in three children.

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836490.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dermatologic Agents; 83HN0GTJ6D / Cyclosporine
  • [Number-of-references] 31
  •  go-up   go-down


29. Inoue CN, Chiba Y, Morimoto T, Nishio T, Kondo Y, Adachi M, Matsutani S: Tonsillectomy in the treatment of pediatric Henoch-Schönlein nephritis. Clin Nephrol; 2007 May;67(5):298-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonsillectomy in the treatment of pediatric Henoch-Schönlein nephritis.
  • We report our experience performing tonsillectomy combined with steroid therapy for 16 pediatric proteinuric Henoch-Schönlein nephritis (HSN) patients.
  • Renal biopsy findings performed in 6 patients were Grade II (3), Grade III (2) and Grade IV (1) according to the International Study of Kidney Diseases in childhood classification.
  • The interval between therapy initiation and complete remission was 9.6 +/- 2.0 months (range 2 - 26 months).

  • MedlinePlus Health Information. consumer health - Tonsillitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542339.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


30. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, Bugarin C, Veltroni M, Michelotto B, Ratei R, Coliva T, Valsecchi MG, Biondi A, Dworzak MN, I-BFM-ALL-FCM-MRD Study Group: Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia; 2005 Jan;19(1):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
  • However, we previously noticed modulation of surface antigen expression in acute lymphoblastic leukemia (ALL) during the early treatment.
  • Hence, we investigated this in 30 children with B-cell precursor ALL consecutively enrolled in the AIEOP-BFM ALL 2000 protocol.
  • Quantitative expression of seven antigens useful in MRD monitoring was studied at diagnosis and compared to that measured at different time points of remission induction therapy.
  • [MeSH-major] Neoplasm, Residual. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Antigens, CD / immunology. Child. Cohort Studies. Humans. Immunophenotyping. Polymerase Chain Reaction. Remission Induction

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2005 Oct;19(10):1858 [16107890.001]
  • [CommentIn] Leukemia. 2005 Oct;19(10):1845-7 [16107891.001]
  • (PMID = 15538405.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


31. Clayton TH, Clark SM, Turner D, Goulden V: The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol; 2007 Jan;32(1):28-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy.
  • Their clinical notes were reviewed for information on age, sex, skin type, minimal erythema dose (MED), adjuvant therapy, previous therapy, adverse effects, number of exposures, cumulative dose, response to treatment and length of remission.
  • Overall, the treatment was well tolerated and the median length of remission was 3 months.

  • Genetic Alliance. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305905.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Binder B, Weger W, Komericki P, Kopera D: Treatment of molluscum contagiosum with a pulsed dye laser: Pilot study with 19 children. J Dtsch Dermatol Ges; 2008 Feb;6(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Molluscum contagiosum is a common, self-limiting viral disease of childhood caused by a poxvirus.
  • In 84.3% one laser treatment led to total remission.
  • In 10.5% a further laser session was necessary and one patient was treated three times to achieve total remission.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LIDOCAINE .
  • Hazardous Substances Data Bank. PRILOCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17995966.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / EMLA; 046O35D44R / Prilocaine; 98PI200987 / Lidocaine
  •  go-up   go-down


33. Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA: Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol; 2008 Jun 20;26(18):3046-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
  • PURPOSE: We aimed to identify relapse predictors in children with a B-cell precursor acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21), a novel genetic entity associated with poor outcome.
  • RESULTS: Twenty-five patients were good responders to prednisone, and all achieved remission after induction therapy.
  • CONCLUSION: The overall and early relapse rates in the BFM study were lower than that in a previous United Kingdom Medical Research Council/Childhood Leukemia Working Party study (38% v 61% and 27% v 47%, respectively), which might result from more intensive induction and early reintensification therapy in the ALL-BFM protocols.
  • [MeSH-major] Chromosomes, Human, Pair 21. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E, Gadner H, Stary J, Benoit Y, Zimmermann M, Reiter A, Riehm H, Masera G, Schrappe M: Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet; 2007 Jan 13;369(9556):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
  • BACKGROUND: Studies in the 1970s and 1980s suggested that the outcome of childhood acute lymphoblastic leukaemia (ALL) could be improved by intensification of conventional continuation chemotherapy with pulses of vincristine sulfate and steroids.
  • At the beginning of the continuation-therapy phase, those patients in complete remission were randomly assigned to either a treatment or a control group.
  • FINDINGS: 174 patients (5.6%) relapsed or died in complete remission before randomisation.
  • With median follow-up of 4.8 years, 240 children in the treatment group and 241 in the control group had relapses; 15 in the treatment group and 14 controls died in complete remission or developed second malignant neoplasms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2007 Jan 13;369(9556):82-3 [17223452.001]
  • (PMID = 17223475.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00411541
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


35. Scheinemann K, Weitzman S, Hitzler J, Doyle J, Abla O: Isolated central nervous system relapse in childhood acute promyelocytic leukemia. J Pediatr Hematol Oncol; 2008 Feb;30(2):160-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system relapse in childhood acute promyelocytic leukemia.
  • Central nervous system (CNS) involvement is rare in acute promyelocytic leukemia (APL).
  • A second remission was achieved with a regimen consisting of intrathecal chemotherapy, intravenous high-dose cytarabine, and oral 6-mercaptopurine.
  • The patient remains in molecular remission at 9 months after autologous stem cell transplant.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Leukemia, Promyelocytic, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376270.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


36. Ay Y, Gokben S, Serdaroglu G, Polat M, Tosun A, Tekgul H, Solak U, Kesikci H: Neuropsychologic impairment in children with rolandic epilepsy. Pediatr Neurol; 2009 Nov;41(5):359-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although patients with benign childhood epilepsy with centrotemporal spikes exhibit normal intelligence, they frequently display neuropsychologic abnormalities.
  • Reading disability persisted in patients in remission from seizures and epileptic discharges.

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818938.001).
  • [ISSN] 1873-5150
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Jimeno-Ruiz S, Martín-Molina R, García-Pérez A, Martínez-Granero M, Bueno Horcajadas A, Martínez-Pérez A: [Carpal tunnel syndrome in childhood.]. Neurologia; 2009 Dec;24(10):849-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carpal tunnel syndrome in childhood.].
  • On top of this, its rarity in childhood makes it difficult to diagnose.
  • Evolution was favorable in the idiopathic cases, one of them with an almost complete remission of symptoms, while the patient with a familial CTS follows a progressive course and is waiting for the surgical assessment.
  • Discussion. The CTS in pediatric age presents milder and more unspecific symptoms than in adults, and the results of the exploration and provocation tests are often unclear.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20340061.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] Spain
  •  go-up   go-down


38. Jiang H, Gu LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J, Xu C, Dong L, Zhou M: [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun;10(3):290-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
  • OBJECTIVE: To study the prognostic factors for events-free survival (EFS) in children with acute non-mature B-lymphoblastic leukemia.
  • METHODS: One hundred and sixty-one children with newly diagnosed acute non-mature B-lymphoblastic leukemia received the ALL-XH-99 protocol treatment.
  • Their medical data, including clinical, biological and molecule features, early responses to treatment (bone marrow evaluation on the 19th day of induction therapy), minimal residual disease (MRD) in bone marrow after remission induction therapy, the risk grade of disease before the beginning of chemotherapy and the outcome, were retrospectively studied.
  • CONCLUSIONS: WBC >or=50 x 10(9)/L, Cmu positive, BCR/ABL or MLL/AF4 positive and MRD positive have important prognostic values in childhood acute non-mature B-lymphoblastic leukemia.
  • [MeSH-major] Burkitt Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Genes, abl. Humans. Infant. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm, Residual. Oncogene Proteins, Fusion / genetics. Prognosis. Regression Analysis


39. Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M, Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group: Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer; 2009 May;52(5):591-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan.
  • BACKGROUND AND PROCEDURE: To assess the clinical course with response to second-line treatment and to evaluate the role of hematopoietic stem cell transplantation (SCT) in children with relapsed or primary refractory lymphoblastic lymphoma (LBL), we analyzed data of 48 patients with relapsed/primary refractory diseases among 260 LBL patients identified in a national survey of 1996-2004.
  • RESULTS: Twenty-six patients achieved second complete remission; 9 achieved partial remission.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19156862.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


40. Hou X, Wang S, Zhou Y, Xu Z, Zou Y, Zhu X, Han M, Pang T, Han ZC: Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol; 2005 Oct;82(3):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.
  • Correlation between genetic polymorphism of A870G of CCND1 and clinical outcome among patients with acute lymphoblastic leukemia (ALL) has been reported.
  • Stratification of patients according to cell type, risk level, and chemotherapeutic response showed significance for the AA genotype in T-cell ALL, ALL with high risk, and no complete remission (P = .047, P = .011, and P = .007, respectively).
  • [MeSH-major] Cyclin D1 / genetics. Exons / genetics. Genetic Predisposition to Disease. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


41. Heuschkel R: Synergy between immunosuppressive therapy and enteral nutrition in the management of childhood Crohn's disease. JPEN J Parenter Enteral Nutr; 2005 Jul-Aug;29(4 Suppl):S160-3; discussion S163-5, S184-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergy between immunosuppressive therapy and enteral nutrition in the management of childhood Crohn's disease.
  • Induction of a remission in children with Crohn's disease is increasingly successful.
  • However this success is dependent on what measure we use to define "remission."
  • Achieving a clinical remission is possible in >70% of children with Crohn's disease at diagnosis, while a mucosal or even immunological remission may occur in <50%.
  • The importance of what ;degree of remission' should be achieved during maintenance therapy is discussed.
  • Whole protein formulae are safe and effective at achieving a clinical remission, however they are not a long-term maintenance strategy.
  • [MeSH-minor] Child. Drug Synergism. Drug Therapy, Combination. Humans. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980278.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 30
  •  go-up   go-down


42. Trobaugh-Lotrario AD, Kletzel M, Quinones RR, McGavran L, Proytcheva MA, Hunger SP, Malcolm J, Schissel D, Hild E, Giller RH: Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant; 2005 Jan;35(2):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT).
  • Pediatric acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with monosomy 7 is associated with poor disease-free survival when treated by conventional chemotherapy, immunosuppression or supportive measures.
  • Toxicity caused deaths of the five nonsurviving patients, four of whom were transplanted with active leukemia.
  • Allogeneic HSCT is effective therapy for childhood AML and MDS associated with monosomy 7, particularly for patients with AML in complete remission and MDS.
  • [MeSH-major] Chromosomes, Human, Pair 7. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / therapy. Monosomy. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Cause of Death. Child. Child, Preschool. Disease Management. Female. Humans. Male. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous. Treatment Outcome


43. Stark W, Huppke P, Gärtner J: Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence. J Neurol; 2008 Dec;255 Suppl 6:119-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric multiple sclerosis: the experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence.
  • We describe a cohort of paediatric MS patients treated in the German Centre for Multiple Sclerosis in Childhood and Adolescence.
  • The course of the disease was more benign than in adult MS with a very slow EDSS increase and complete remission after most relapses.


44. He J, Chen ZX, Xue YQ, Pan JL, He HL, Li JQ, Wu YF, Huang YP, Zhu LL: [Study on clinical and biological characteristics of childhood acute leukemia with MLL gene rearrangements]. Zhonghua Xue Ye Xue Za Zhi; 2005 Aug;26(8):477-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on clinical and biological characteristics of childhood acute leukemia with MLL gene rearrangements].
  • OBJECTIVE: To study the clinical and laboratory features of childhood acute leukemia (AL) with MLL gene rearrangements.
  • METHODS: Sixteen of 298 cases of childhood AL with MLL rearrangements were studied by using MLL dual-color FISH, multiplex RT-PCR with 13 pairs of primers in combination with R banding karyotype analysis and cell immunophenotyping by flow cytometry.
  • RESULTS: Sixteen cases of childhood AL with MLL rearrangements accounted for 5.4% of 298 AL patients, and 56.3% of infant ALs.
  • Of these 16 patients, 8 received chemotherapy and 7 of them achieved complete remission, while the other 8 patients gave up treatment.
  • Finding out MLL gene rearrangement is of most importance in guiding therapy and predicting prognosis in childhood AL.
  • [MeSH-major] Gene Rearrangement. Leukemia / genetics. Myeloid-Lymphoid Leukemia Protein / genetics

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383239.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


45. Cigarroa López JA, García Jiménez Y, Yáñez Gutiérrez L, Jiménez Arteaga S, Martínez Sánchez A, Ortegón Cardeña J, Gómez FD, Sánchez Soberanes A, López Gallegos D, Riera-Kinkel C, Alva Espinosa C: [Cardiac rhabdomyoma surgically treated with success. Review of literature]. Arch Cardiol Mex; 2005 Jul-Sep;75 Suppl 3:S3-113-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The more frequent tumors during the childhood are the cardiac rhabdomyomas.
  • [MeSH-minor] Humans. Infant, Newborn. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366176.001).
  • [ISSN] 1405-9940
  • [Journal-full-title] Archivos de cardiología de México
  • [ISO-abbreviation] Arch Cardiol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 18
  •  go-up   go-down


46. Yabe M, Sako M, Yabe H, Osugi Y, Kurosawa H, Nara T, Tokuyama M, Adachi S, Kobayashi C, Yanagimachi M, Ohtsuka Y, Nakazawa Y, Ogawa C, Manabe A, Kojima S, Nakahata T, Japanese Childhood MDS Study Group: A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatr Transplant; 2008 Dec;12(8):862-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
  • Five patients developed acute GVHD and two developed chronic GVHD.
  • Seven patients are alive and in remission 27-69 months after transplantation.
  • [MeSH-major] Busulfan / administration & dosage. Immunosuppressive Agents / therapeutic use. Leukemia, Myelomonocytic, Juvenile / drug therapy. Melphalan / administration & dosage. Stem Cell Transplantation / methods. Vidarabine / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Child. Child, Preschool. Female. History, Ancient. Humans. Male. Pilot Projects. Remission Induction. Transplantation Conditioning / methods. Transplantation, Homologous / methods

  • Genetic Alliance. consumer health - Juvenile Myelomonocytic Leukemia (JMML).
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397212.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


47. Pawińska-Wasikowska K, Balwierz W: [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia]. Przegl Lek; 2010;67(6):361-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
  • Leukemias are the most common malignancy in children, and acute lymphoblastic leukemia (ALL) accounts for 85% of all childhood leukemias.
  • Identification of leukemia associated phenotype (LAP), used for cell analysis in sequential time points, with a set monoclonal antibodies panel, was possible in all analyzed patients.
  • [MeSH-major] Antigenic Modulation / immunology. Antigens, CD / analysis. Neoplasm, Residual / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / analysis. Child. Child, Preschool. Drug Monitoring. Female. Flow Cytometry. Humans. Infant. Male. Remission Induction / methods


48. Hafiz MG, Islam A, Siddique R: Back pain and vertebral compression: an unusual presentation of childhood acute lymphoblastic leukemia. Mymensingh Med J; 2010 Jan;19(1):130-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Back pain and vertebral compression: an unusual presentation of childhood acute lymphoblastic leukemia.
  • Two weeks before admission, the hematological findings were suggestive of leukemia of lymphoblastic type.
  • Bone marrow morphology study and the cytochemistry of the aspirated marrow were consistent with acute lymphoblastic leukemia (ALL-L2).
  • Then, he was started protocol based chemotherapy for induction of remission, consolidation, high dose methotrexate and maintenance therapy.


49. Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B, French Pediatric-Onset SLE Study Group: Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr; 2006 May;148(5):623-627
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy for childhood-onset systemic lupus erythematosus.
  • OBJECTIVE: To describe the safety and efficacy of rituximab in the treatment of childhood-onset systemic lupus erythematosus (SLE).
  • STUDY DESIGN: We conducted a French multicenter retrospective study of childhood-onset SLE treated with rituximab.
  • Remission was achieved in 6 of 8 patients with lupus nephritis and in the 2 patients with autoimmune cytopenia.
  • The mean follow-up period was 13.2 months (range, 6-26 months), and remission lasted in all who patients who responded to treatment, except 1 patient who was successfully retreated with a second course of rituximab.
  • Effective depletion of peripheral blood B cells was observed in 7 of 8 patients who were examined, and this paralleled the remission.

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr. 2006 May;148(5):571-3 [16737861.001]
  • [ErratumIn] J Pediatr. 2006 Oct;149(4):586
  • (PMID = 16737873.001).
  • [ISSN] 0022-3476
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


50. Tamam L, Tuğlu C, Karatas G, Ozcan S: Adult attention-deficit hyperactivity disorder in patients with bipolar I disorder in remission: preliminary study. Psychiatry Clin Neurosci; 2006 Aug;60(4):480-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult attention-deficit hyperactivity disorder in patients with bipolar I disorder in remission: preliminary study.
  • Attention-deficit hyperactivity disorder (ADHD), a syndrome that typically first appears in early childhood, can occur in individuals of all ages.


51. Caraballo RH, Cersósimo RO, Fejerman N: Late-onset, "Gastaut type", childhood occipital epilepsy: an unusual evolution. Epileptic Disord; 2005 Dec;7(4):341-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset, "Gastaut type", childhood occipital epilepsy: an unusual evolution.
  • We report on two girls and one boy with clinical and electroencephalographic features of late-onset childhood epilepsy with occipital paroxysms of the "Gastaut type", showing an unusual evolution.
  • These three patients, with typical electroclinical features of "Gastaut type", childhood occipital epilepsy, demonstrated an evolution which, to our knowledge, has not been previously described.
  • [MeSH-minor] Age of Onset. Anticonvulsants / therapeutic use. Child. Disease Progression. Female. Hallucinations / etiology. Humans. Male. Migraine Disorders / etiology. Photic Stimulation. Remission, Spontaneous. Seizures, Febrile / genetics. Sleep Disorders, Intrinsic / etiology

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338677.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


52. Vora A, Mitchell CD, Lennard L, Eden TO, Kinsey SE, Lilleyman J, Richards SM, Medical Research Council, National Cancer Research Network Childhood Leukaemia Working Party: Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet; 2006 Oct 14;368(9544):1339-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
  • BACKGROUND: 6-mercaptopurine has been a standard component of long-term continuing treatment for childhood lymphoblastic leukaemia, whereas 6-thioguanine has been mainly used for intensification courses.
  • Since preliminary data have shown that 6-thioguanine is more effective than 6-mercaptopurine, we compared the efficacy and toxicity of the two drugs for childhood lymphoblastic leukaemia.
  • METHODS: Consecutive children with lymphoblastic leukaemia diagnosed in the UK and Ireland between April, 1997, and June, 2002, were randomly assigned either 6-thioguanine (750 patients) or 6-mercaptopurine (748 patients) during interim maintenance and continuing therapy.
  • Although 6-thioguanine conferred a significantly lower risk of isolated CNS relapse than did 6-mercaptopurine (odds ratio [OR] 0.53, 95% CI 0.30-0.92, p=0.02), the benefit was offset by an increased risk of death in remission (2.22, 1.20-4.14, p=0.01), mainly due to infections during continuing therapy.
  • 6-mercaptopurine should remain the thiopurine of choice for continuing therapy of childhood lymphoblastic leukaemia.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thioguanine / therapeutic use


53. Arya LS, Kotikanyadanam SP, Bhargava M, Saxena R, Sazawal S, Bakhshi S, Khattar A, Kulkarni KP, Adde M, Vats TS, Magrath I: Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol. J Pediatr Hematol Oncol; 2010 Jul;32(5):370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol.
  • Two hundred twenty-three (87.8%) children achieved a complete remission of whom 40 (17.9%) relapsed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Humans. Infant. Male. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome


54. Tsurusawa M, Taga T, Horikoshi Y, Ogawa A, Kikuta A, Kanegane H, Matsushita T, Hyakuna N, Shimomura Y, Ohshima K, Lymphoma Committee of Japanese Childhood Cancer and Leukemia: Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group. Leuk Lymphoma; 2008 Apr;49(4):734-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese Childhood Cancer and Leukemia Study Group.
  • All children achieved a complete remission.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide. Doxorubicin / analogs & derivatives. Follow-Up Studies. Humans. Infant. Japan. Methotrexate. Prednisolone. Remission Induction. Survival Analysis. Treatment Outcome. Vincristine

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398741.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; D58G680W0G / pirarubicin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


55. Deng F, Lu L, Zhang Q, Hu B, Wang SJ, Huang N: Henoch-Schönlein purpura in childhood: treatment and prognosis. Analysis of 425 cases over a 5-year period. Clin Rheumatol; 2010 Apr;29(4):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Henoch-Schönlein purpura in childhood: treatment and prognosis. Analysis of 425 cases over a 5-year period.
  • The remission time of skin, joint, and gastrointestinal manifestations was evaluated, and the results of the follow-up were analyzed (remission time of proteinuria, relapse, and side effects of therapy).

  • Genetic Alliance. consumer health - Henoch-Schonlein purpura.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Nephrol. 2004 Jan;19(1):51-6 [14634864.001]
  • [Cites] Medicine (Baltimore). 1999 Nov;78(6):395-409 [10575422.001]
  • [Cites] Pediatr Nephrol. 2003 Apr;18(4):347-50 [12700960.001]
  • [Cites] Medicine (Baltimore). 2001 Sep;80(5):279-90 [11552081.001]
  • [Cites] Kidney Int. 2008 Sep;74(5):596-612 [18509322.001]
  • [Cites] Pediatr Nephrol. 2007 Oct;22(10):1717-22 [17647023.001]
  • [Cites] Lancet. 2002 Aug 31;360(9334):666-70 [12241872.001]
  • [Cites] Arch Dis Child. 2009 Feb;94(2):132-7 [18701559.001]
  • [Cites] J Pediatr. 2006 Aug;149(2):241-7 [16887443.001]
  • [Cites] J Pediatr. 2000 Mar;136(3):370-5 [10700695.001]
  • [Cites] Clin Nephrol. 2003 Aug;60(2):80-4 [12940608.001]
  • [Cites] Curr Opin Rheumatol. 2001 Jan;13(1):35-40 [11148713.001]
  • [Cites] Semin Arthritis Rheum. 2005 Dec;35(3):143-53 [16325655.001]
  • [Cites] Clin Rheumatol. 2008 Sep;27(9):1087-92 [18305976.001]
  • [Cites] Pediatr Nephrol. 2001 Nov;16(11):901-5 [11685598.001]
  • [Cites] Lancet. 1992 Feb 1;339(8788):280-2 [1346291.001]
  • [Cites] Ann Rheum Dis. 2006 Jul;65(7):936-41 [16322081.001]
  • [Cites] Pediatr Nephrol. 1998 Apr;12(3):238-43 [9630046.001]
  • [Cites] Curr Opin Rheumatol. 1994 Jan;6(1):25-31 [8031676.001]
  • [Cites] Clin Pediatr (Phila). 2007 Jul;46(6):505-11 [17579102.001]
  • [Cites] Pediatr Nephrol. 2005 Aug;20(8):1087-92 [15889281.001]
  • [Cites] Pediatrics. 2007 Nov;120(5):1079-87 [17974746.001]
  • (PMID = 20033243.001).
  • [ISSN] 1434-9949
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Plant Extracts; LIU00Z1Z84 / cortisol succinate; WI4X0X7BPJ / Hydrocortisone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


56. Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH, Downing JR, Campana D: A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood; 2007 Aug 15;110(4):1271-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
  • To identify novel predictors of outcome in childhood acute lymphoblastic leukemia (ALL), we analyzed gene expression in the leukemic cells of 187 children with newly diagnosed ALL and compared the findings with minimal residual disease (MRD) results obtained on day 19 of remission induction treatment.
  • The biologic processes regulated by the genes we identified appear to be key determinants of the early cytoreductive response to remission induction therapy and subsequent clinical outcome in childhood ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1986 Nov 7;234(4777):697-704 [3535067.001]
  • [Cites] Cancer. 1978 Aug;42(2 Suppl):828-38 [356955.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1653-60 [7564505.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):389-98 [8636748.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):603-6 [9207407.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Br J Haematol. 1998 Jun;101(3):548-51 [9633900.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2908-15 [15576476.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1189-98 [15878973.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19069-74 [16354839.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):818-23 [16628000.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5092-6 [11016634.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Dev Biol. 2001 May 15;233(2):305-18 [11336497.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):409-17 [11905735.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):109-16 [12527913.001]
  • [Cites] Leukemia. 2003 Mar;17(3):532-40 [12646941.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):666-71 [12915875.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Mol Cancer Ther. 2004 Oct;3(10):1207-14 [15486187.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [CommentIn] Blood. 2008 Feb 15;111(4):2486-7; author reply 2487-8 [18263786.001]
  • (PMID = 17456722.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1939904
  •  go-up   go-down


57. Mandal C, Tringali C, Mondal S, Anastasia L, Chandra S, Venerando B, Mandal C: Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells. Int J Cancer; 2010 Jan 15;126(2):337-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells.
  • In this report, we demonstrated that acute lymphoblastic leukemia (ALL), lymphoblasts (primary cells from patients and cell lines) are characterized by a marked down-regulation of Neu3 in terms of both gene expression (-30 to 40%) and enzymatic activity toward ganglioside GD1a (-25.6 to 30.6%), when compared with cells from healthy controls.
  • Interestingly, we found that Neu3 activity varied in relation to disease progression, increasing in clinical remission after chemotherapy, and decreasing again in patients that relapsed.
  • Consequently, Neu3 could represent a new potent biomarker in childhood ALL, to assess the efficacy of therapeutic protocols and to rapidly identify an eventual relapse.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / metabolism. Membrane Proteins / metabolism. Neuraminidase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588508.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Sphingolipids; EC 3.2.1.18 / NEU2 protein, human; EC 3.2.1.18 / Neu3 protein, human; EC 3.2.1.18 / Neuraminidase; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


58. Camfield P, Camfield C: Idiopathic generalized epilepsy with generalized tonic-clonic seizures (IGE-GTC): a population-based cohort with &gt;20 year follow up for medical and social outcome. Epilepsy Behav; 2010 May;18(1-2):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children with idiopathic generalized epilepsy with only generalized tonic-clonic seizures (IGE-GTC) were selected from the Nova Scotia Childhood Epilepsy population-based cohort.
  • Twenty-seven (75%) had a complete terminal remission (seizure-free, off medication) for 16.1+/-8.6 years.
  • IGE-GTC is a recognizable, relatively benign epilepsy syndrome with complete remission in 75%.

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Seizures.
  • Genetic Alliance. consumer health - Idiopathic generalized epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20471324.001).
  • [ISSN] 1525-5069
  • [Journal-full-title] Epilepsy & behavior : E&B
  • [ISO-abbreviation] Epilepsy Behav
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


59. Ye QD, Tang JY, Pan C, Chen J, Xue HL, Chen J, Dong L, Zhou M, Shen SH: [Therapeutic experience of childhood stage III neuroblastoma]. Zhonghua Yi Xue Za Zhi; 2010 Jun 8;90(22):1556-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic experience of childhood stage III neuroblastoma].
  • OBJECTIVE: To evaluate the long-term outcomes of childhood stage III neuroblastoma (NB) and its associated prognostic factors.
  • A complete response or an excellent partial remission was observed in 28 patients.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973238.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


60. Silverstein DM, Craver R: Presenting features and short-term outcome according to pathologic variant in childhood primary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol; 2007 Jul;2(4):700-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presenting features and short-term outcome according to pathologic variant in childhood primary focal segmental glomerulosclerosis.
  • At last follow-up among all patients, 71% were in remission, 78% had stage 1 or 2 chronic kidney disease, and 4.9% had reached ESRD.
  • Remission after the initial course of corticosteroids was less common with the collapsing variant.
  • CONCLUSIONS: The short-term outcome in pediatric primary FSGS is generally favorable, but a more guarded prognosis exists for patients with collapsing FSGS.

  • Genetic Alliance. consumer health - Focal Segmental Glomerulosclerosis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699485.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


61. Klein O, Joud A, Marchal JC: [Management of benign intracranial hypertension: analysis of the Nancy series]. Neurochirurgie; 2008 Dec;54(6):710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Benign intracranial hypertension (BIH) is a rare condition, especially in childhood.
  • The aim of this study was to analyze retrospectively pediatric cases that were diagnosed and managed in the same institution during the 2002-2006 period.
  • One child is in complete remission after depletive LP only.

  • Genetic Alliance. consumer health - Intracranial Hypertension.
  • Hazardous Substances Data Bank. ACETAZOLAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004459.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; O3FX965V0I / Acetazolamide
  •  go-up   go-down


62. Voronkova KV, Pylaeva OA, Petrukhin AS: Efficacy of topiramate (Topamax) in epileptic patients of different ages. Neurosci Behav Physiol; 2007 Jul;37(6):547-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This agent was used as monotherapy and combined therapy in 114 patients (53 male, 61 female) of the following age groups: early childhood (16), preschool and school age (20), pubertal (16), young (23), adult (38), and elderly (1).
  • Treatment produced complete clinical remission in 48% of patients and decreases in fit frequency by more than 50% in 44% of patients.
  • In terms of remission, Topamax was more effective in adolescents, youths and adults than in younger children, and this pattern was also seen in the treatment of symptomatic epilepsy.

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. TOPIRAMATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2003 Jan 28;60(2):196-202 [12552030.001]
  • [Cites] Neurology. 2004 Nov 23;63(10 Suppl 4):S40-8 [15557550.001]
  • [Cites] Epilepsy Res. 2001 Mar;43(3):255-60 [11248537.001]
  • [Cites] Neurology. 1999 Apr 22;52(7):1338-44 [10227615.001]
  • [Cites] Epilepsia. 2004 Dec;45(12):1478-87 [15571505.001]
  • [Cites] Epilepsia. 1996 Aug;37(8):763-8 [8764816.001]
  • [Cites] Epilepsia. 1997;38 Suppl 1:S37-41 [9092958.001]
  • [Cites] Acta Neurol Scand. 2003 Mar;107(3):165-75 [12614309.001]
  • [Cites] J Child Neurol. 2004 Aug;19(8):588-91 [15605467.001]
  • [Cites] Epilepsia. 1997 Mar;38(3):294-300 [9070591.001]
  • [Cites] Epilepsia. 1997;38 Suppl 1:S34-6 [9092957.001]
  • [Cites] Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(8):35-40 [15554140.001]
  • [Cites] Pediatr Neurol. 2004 Nov;31(5):349-52 [15519117.001]
  • [Cites] Paediatr Drugs. 2001;3(4):293-319 [11354701.001]
  • (PMID = 17657424.001).
  • [ISSN] 0097-0549
  • [Journal-full-title] Neuroscience and behavioral physiology
  • [ISO-abbreviation] Neurosci. Behav. Physiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0H73WJJ391 / topiramate; 30237-26-4 / Fructose
  •  go-up   go-down


63. Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, Darbyshire PJ, Lancaster D, Hann I, Eden T, Saha V: Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol; 2005 Jul;130(1):67-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial.
  • A retrospective analysis of children with first relapse of acute lymphoblastic leukaemia (ALL), treated on the UKALL R2 protocol at four different hospitals, between June 1995 and December 2002 was performed.
  • Of the 150 children 139 (93%) achieved a second complete remission.
  • The duration of first complete remission and immunophenotype, but not sites of relapse, were predictive for survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Asparaginase / administration & dosage. Child. Combined Modality Therapy. Disease-Free Survival. Epirubicin / administration & dosage. Female. Humans. Male. Prednisolone / administration & dosage. Recurrence. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. United Kingdom. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982346.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


64. Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL: Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood; 2005 Aug 15;106(4):1183-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
  • This open-label, dose-escalation study evaluated the safety and efficacy of single-agent gemtuzumab ozogamicin, a humanized anti-CD33 antibody-targeted chemotherapeutic agent, for pediatric patients with multiple relapsed or primary refractory acute myeloid leukemia (AML).
  • Eight of 29 (28%) patients achieved overall remission.
  • Mean multidrug resistance-protein-mediated drug efflux was significantly lower in the leukemic blasts of patients achieving remission (P < .005).
  • Further studies in combination with standard induction therapy for childhood AML are warranted.
  • [MeSH-major] Aminoglycosides / administration & dosage. Aminoglycosides / toxicity. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / toxicity. Antigens, CD. Antigens, Differentiation, Myelomonocytic. Leukemia, Myeloid / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Acute Disease. Adolescent. Antibodies, Monoclonal, Humanized. Blast Crisis. Child. Child, Preschool. Drug Resistance. Female. Hematopoietic Stem Cell Transplantation. Hepatic Veno-Occlusive Disease / chemically induced. Humans. Hyperbilirubinemia / chemically induced. Infant. Male. Maximum Tolerated Dose. Remission Induction / methods. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886328.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  •  go-up   go-down


65. Gargah T, Goucha-Louzir R, Lakhoua MR: [Interest of mycophenolate mofetil in children with membranous lupus nephritis]. Nephrol Ther; 2010 Dec;6(7):564-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the induction phase, three patients achieved complete remission of their nephrotic syndrome with normalization of renal function.
  • One patient achieved partial remission and kept moderate renal failure.
  • During the maintenance phase, three patients had complete remission.
  • In childhood lupus proliferative glomerulonephritis, MMF was well tolerated, and most of the patients achieved remission and improvement of their renal functions.

  • Genetic Alliance. consumer health - Lupus.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20829140.001).
  • [ISSN] 1872-9177
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


66. Shin JI, Park JM, Lee SM, Shin YH, Kim JH, Lee JS, Kim MJ: Factors affecting spontaneous resolution of hematuria in childhood nutcracker syndrome. Pediatr Nephrol; 2005 May;20(5):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting spontaneous resolution of hematuria in childhood nutcracker syndrome.
  • [MeSH-minor] Adolescent. Aorta. Blood Flow Velocity. Body Mass Index. Child. Child, Preschool. Female. Humans. Male. Mesenteric Artery, Superior. Remission, Spontaneous. Retrospective Studies. Ultrasonography, Doppler

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplant Proc. 2003 Mar;35(2):851-3 [12644163.001]
  • [Cites] J Ultrasound Med. 1994 Jul;13(7):569-74 [7933021.001]
  • [Cites] Clin Nephrol. 1998 Jan;49(1):35-40 [9491284.001]
  • [Cites] Radiology. 1982 Dec;145(3):647-50 [7146391.001]
  • [Cites] Nephrol Dial Transplant. 2001 Aug;16(8):1620-5 [11477164.001]
  • [Cites] Clin Nephrol. 1988 Sep;30(3):134-40 [3052954.001]
  • [Cites] Clin Exp Nephrol. 2004 Mar;8(1):68-70 [15067520.001]
  • [Cites] Radiology. 1996 Jan;198(1):93-7 [8539413.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jan;172(1):39-43 [9888735.001]
  • [Cites] Urology. 1982 Oct;20(4):365-9 [7147503.001]
  • [Cites] J Urol. 1991 Sep;146(3):685-8 [1875472.001]
  • [Cites] J Ultrasound Med. 2002 Jan;21(1):39-45; quiz 46 [11794401.001]
  • [Cites] Urology. 2002 Mar;59(3):354-7 [11880069.001]
  • [Cites] Pediatr Nephrol. 1990 Jul;4(4):324-7 [1698439.001]
  • [Cites] Br J Urol. 1994 Aug;74(2):139-43 [7921927.001]
  • [Cites] Eur Urol. 1978;4(2):115-9 [631152.001]
  • [Cites] Pediatr Nephrol. 1997 Apr;11(2):218-20 [9090670.001]
  • [Cites] Pediatr Radiol. 1991;21(4):267-9 [1870922.001]
  • [Cites] Urology. 1978 Jul;12 (1):40-9 [98890.001]
  • [Cites] Clin Nephrol. 1999 Apr;51(4):259-60 [10230562.001]
  • [Cites] J Urol. 1980 Jul;124(1):12-6 [7411696.001]
  • [Cites] J Urol. 1997 May;157(5):1833-4 [9112534.001]
  • [Cites] Int Urol Nephrol. 1990;22(1):3-6 [2199393.001]
  • [Cites] J Belge Radiol. 1972 Sep-Oct;55(5):507-11 [4660828.001]
  • [Cites] J Vasc Interv Radiol. 1996 Nov-Dec;7(6):859-61 [8951753.001]
  • [Cites] Pediatr Nephrol. 2000 Sep;14(10-11):1002-5 [10975316.001]
  • (PMID = 15772835.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Kolenova A, Hikkel I, Ilencikova D, Hikkelova M, Sejnova D, Kaiserova E, Cizmar A, Puskacova J, Bubanska E, Oravkinova I, Gencik M: Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience. Neoplasma; 2010;57(6):552-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
  • Acute lymphoblastic leukemia is the most common form of cancer in children.
  • The 10-year event-free survival ranged from 77 to 85% after having achieved complete remission rates of 93% or higher.
  • An intense effort has been made to develop methods to determine the degree of minimal residual leukemia cells present in patients considered to be in morphological remission.
  • A total of 40 patients with BCP-ALL ( B cell precursor ALL) and 4 patients with T ALL were analyzed for Ig/TCR rearrangement.
  • [MeSH-major] Gene Rearrangement. Gene Rearrangement, T-Lymphocyte. Genes, Immunoglobulin. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845994.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


68. Wei ZG, Tang LF, Chen ZM, Tang HF, Li MJ: Childhood undifferentiated embryonal liver sarcoma: clinical features and immunohistochemistry analysis. J Pediatr Surg; 2008 Oct;43(10):1912-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood undifferentiated embryonal liver sarcoma: clinical features and immunohistochemistry analysis.
  • PURPOSE: The aim of the study was to report on 3 cases of childhood undifferentiated embryonal liver sarcoma (UELS) and to highlight the clinical features, laboratory findings, diagnosis, and management of this rare disease.
  • [MeSH-minor] Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Desmin / analysis. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Hepatectomy. Humans. Ifosfamide / administration & dosage. Male. Neoadjuvant Therapy. Remission Induction. Vimentin / analysis. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Embryonal Sarcoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926232.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / Desmin; 0 / Neoplasm Proteins; 0 / Vimentin; 5V9KLZ54CY / Vinblastine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


69. Poyer F, Coquerel B, Pegahi R, Cazin L, Norris V, Vannier JP, Lamacz M: Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia. Leuk Res; 2009 Mar;33(3):407-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia.
  • In children with acute lymphoblastic leukemia (ALL), leukemic cells express several members of the VEGF family and the three VEGF receptors which, via an autocrine loop are responsible for secretion of MMP-2/-9.
  • These data implicate autocrine VEGF-induced secretion of MMP-2/-9 in the physiopathology of childhood ALL.
  • [MeSH-major] Autocrine Communication. Matrix Metalloproteinase 2 / secretion. Matrix Metalloproteinase 9 / secretion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Vascular Endothelial Growth Factor A / physiology. Vascular Endothelial Growth Factor Receptor-1 / analysis. Vascular Endothelial Growth Factor Receptor-3 / analysis
  • [MeSH-minor] Adolescent. Biomarkers / analysis. Child. Child, Preschool. Hemoglobins / analysis. Humans. Infant. Prognosis. Remission Induction. Treatment Failure. Tumor Lysis Syndrome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829111.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Hemoglobins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


70. Abeyagunawardena AS, Hindmarsh P, Trompeter RS: Adrenocortical suppression increases the risk of relapse in nephrotic syndrome. Arch Dis Child; 2007 Jul;92(7):585-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Children with nephrotic syndrome (NS) are usually treated with long-term low dose alternate day prednisolone with or without glucocorticoid sparing therapy, such as levamisole or ciclosporin, to maintain remission.

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. Cosyntropin .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):88-92 [9435421.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Feb;44(2):137-40 [8849565.001]
  • [Cites] J Am Soc Nephrol. 1999 Mar;10(3):529-37 [10073603.001]
  • [Cites] Arch Dis Child. 1999 Apr;80(4):330-3 [10086937.001]
  • [Cites] Expert Opin Pharmacother. 2002 May;3(5):513-9 [11996630.001]
  • [Cites] Pediatr Nephrol. 2003 Sep;18(9):919-24 [12883981.001]
  • [Cites] Arch Dis Child. 2004 Nov;89(11):1055-8 [15499064.001]
  • [Cites] Lancet. 1971 Oct 9;2(7728):778-80 [4106604.001]
  • [Cites] Lancet. 1974 Sep 7;2(7880):556-60 [4140273.001]
  • [Cites] Lancet. 1977 Oct 15;2(8042):795-6 [71603.001]
  • [Cites] Br Med J. 1978 Apr 8;1(6117):892 [346147.001]
  • [Cites] Am J Dis Child. 1982 Aug;136(8):732-6 [7048898.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Aug;47(2):272-4 [233665.001]
  • [Cites] J Pediatr. 1983 Oct;103(4):553-7 [6312005.001]
  • [Cites] Lancet. 1985 Feb 16;1(8425):368-70 [2857421.001]
  • [Cites] J Pediatr. 1986 Mar;108(3):378-82 [3005537.001]
  • [Cites] Acta Paediatr Scand. 1986 Sep;75(5):804-10 [2436435.001]
  • [Cites] Lancet. 1988 May 28;1(8596):1208-10 [2897016.001]
  • [Cites] J Endocrinol. 1993 Jan;136(1):167-72 [8429271.001]
  • [Cites] Transplantation. 1993 Sep;56(3):603-9 [8212155.001]
  • [Cites] Arch Dis Child. 1994 Feb;70(2):151-7 [8129444.001]
  • [Cites] Nephron. 1994;66(4):408-12 [8015643.001]
  • [Cites] Pediatr Nephrol. 1994 Aug;8(4):401-3 [7947023.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1301-5 [7714104.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jan;81(1):285-90 [8550765.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Apr;44(4):473-6 [8706316.001]
  • [Cites] QJM. 1998 Apr;91(4):285-90 [9666951.001]
  • (PMID = 17284479.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 16960-16-0 / Cosyntropin; 2880D3468G / Levamisole; 53468-06-7 / adrenocorticotropin zinc; 83HN0GTJ6D / Cyclosporine; 9PHQ9Y1OLM / Prednisolone; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC2083779
  •  go-up   go-down


71. Stevenson DA, Carey JC, Coburn SP, Ericson KL, Byrne JL, Mumm S, Whyte MP: Autosomal recessive hypophosphatasia manifesting in utero with long bone deformity but showing spontaneous postnatal improvement. J Clin Endocrinol Metab; 2008 Sep;93(9):3443-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • His older brother has the childhood form of HPP without findings until after infancy.

  • Genetic Alliance. consumer health - Hypophosphatasia.
  • MedlinePlus Health Information. consumer health - Child Development.
  • MedlinePlus Health Information. consumer health - Infant and Newborn Development.
  • MedlinePlus Health Information. consumer health - Toddler Development.
  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1994 Aug;15(4):439-61 [7988481.001]
  • [Cites] Prenat Diagn. 1985 Jan-Feb;5(1):47-52 [3883342.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3936-42 [9814472.001]
  • [Cites] Hum Mol Genet. 1999 Jun;8(6):1039-46 [10332035.001]
  • [Cites] Am J Med Genet. 1999 Oct 29;86(5):410-5 [10508980.001]
  • [Cites] Am J Med Genet. 1999 Oct 29;86(5):434-8 [10508985.001]
  • [Cites] Lancet. 1955 Jan 15;268(6855):131 [13222868.001]
  • [Cites] Am J Med. 1957 May;22(5):730-46 [13410963.001]
  • [Cites] J Ultrasound Med. 2005 May;24(5):707-9 [15840803.001]
  • [Cites] Eur J Pediatr. 2005 May;164(5):277-82 [15660230.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 5;823(2):218-20 [16054880.001]
  • [Cites] J Pediatr. 2006 Jun;148(6):753-8 [16769381.001]
  • [Cites] Genet Test. 2006 Winter;10(4):252-7 [17253930.001]
  • [Cites] Clin Genet. 1999 Oct;56(4):313-7 [10636450.001]
  • [Cites] Hum Mutat. 2000 Mar;15(3):293 [10679946.001]
  • [Cites] Mol Genet Metab. 2002 Feb;75(2):143-53 [11855933.001]
  • [Cites] J Bone Miner Res. 2003 Apr;18(4):624-36 [12674323.001]
  • [Cites] J Can Assoc Radiol. 1972 Mar;23(1):16-26 [5020955.001]
  • [Cites] Anal Biochem. 1983 Mar;129(2):310-7 [6846830.001]
  • [Cites] J Clin Invest. 1985 Aug;76(2):752-6 [4031070.001]
  • [Cites] Genomics. 1988 Feb;2(2):139-43 [3410475.001]
  • [Cites] Pediatr Pathol. 1988;8(5):483-93 [3227000.001]
  • [Cites] Am J Hum Genet. 1990 Feb;46(2):286-92 [1689104.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9924-8 [1409720.001]
  • [Cites] Am J Med Genet. 1992 Jan 1;42(1):117-21 [1308350.001]
  • [Cites] Medicine (Baltimore). 1984 Jan;63(1):12-24 [6690884.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Dec;81(12):4458-61 [8954059.001]
  • (PMID = 18559907.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS052500; United States / NCRR NIH HHS / RR / M01 RR000064; United States / NCRR NIH HHS / RR / M01-RR00064
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.1 / Alkaline Phosphatase
  • [Other-IDs] NLM/ PMC2567856
  •  go-up   go-down


72. Benmiloud S, Steffens M, Beauloye V, de Wandeleer A, Devogelaer JP, Brichard B, Vermylen C, Maiter D: Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr; 2010;74(4):241-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood.
  • BACKGROUND: Little is known regarding long-term bone deficit in relationship with the modalities of cancer therapy among survivors of childhood malignancy.
  • METHODS: Bone mineral density (BMD) was evaluated at lumbar spine (LS), total hip and femoral neck in 89 patients (44 men) more than 5 years after remission of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL).
  • CONCLUSIONS: A low bone mass is frequently observed in adult survivors of childhood ALL and NHL, and is associated with male gender at the LS and with dexamethasone treatment, cranial irradiation and BMT/TBI at the hip.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Density / drug effects. Bone Density / radiation effects. Lymphoma, Non-Hodgkin / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


73. Jurkowska M, Malinowska I, Bal J: [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood]. Przegl Lek; 2005;62(12):1412-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood].
  • This approach currently results in overall 95% rate of complete remission in paediatric acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786762.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 2.5.1.18 / Glutathione Transferase
  • [Number-of-references] 33
  •  go-up   go-down


74. Martorell-Calatayud A, Hernández-Martín A, Colmenero I, Vañó-Galván S, López-Obregón C, Armand A, Gambra Arzoz M, Torrelo A: [Lymphomatoid papulosis in children: report of 9 cases and review of the literature]. Actas Dermosifiliogr; 2010 Oct;101(8):693-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lymphomatoid papulosis is a rare lymphoproliferative T cell CD30+ disease with excellent prognosis which affects almost exclusively adult patients, being rarely in the childhood; thus the clinic and pathologic spectrum and the risk of evolution to another type of lymphoma are not well defined in the pediatric group.
  • [MeSH-minor] Adolescent. Age of Onset. Child. Child, Preschool. Cicatrix / etiology. Clone Cells / pathology. Diagnosis, Differential. Disease Progression. Female. Humans. Lymphoma, T-Cell, Cutaneous / diagnosis. Male. Pigmentation Disorders / etiology. Pityriasis Lichenoides / complications. Remission, Spontaneous. Retrospective Studies. Skin Pigmentation

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965012.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


75. Rana ZA, Rabbani MW, Sheikh MA, Khan AA: Outcome of childhood acute lymphoblastic leukaemia after induction therapy--3 years experience at a single paediatric oncology centre. J Ayub Med Coll Abbottabad; 2009 Oct-Dec;21(4):150-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of childhood acute lymphoblastic leukaemia after induction therapy--3 years experience at a single paediatric oncology centre.
  • BACKGROUND: Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy.
  • It represents 25% of all childhood cancers and approximately 75% of all cases of childhood leukaemia.
  • Objective was to see the bone marrow remission pattern at the end of induction therapy in paediatric ALL patients in our setup.
  • Bone marrow biopsy was repeated at day 28 of induction therapy and remission pattern was seen.
  • At day 28 of induction therapy, 28 (74%) patients went into complete remission (< 5% blast cells in bone marrow), 2 (5%) into partial remission (5-25% blast cells in bone marrow) and 1 (3%) was not in remission (> 25% blast cells in the bone marrow).
  • Remission can be achieved in most of these patients after induction therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Clinical Protocols. Female. Humans. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067050.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


76. Nguyen-Michel VH, Ourabah Z, Sebban C, Lavallard-Rousseau MC, Adam C: [Idiopathic generalised epilepsies in the elderly: the viewpoint of a geriatrician]. Rev Neurol (Paris); 2009 Nov;165(11):924-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Long-term follow-up studies indicate a low remission rate in idiopathic generalised epilepsies (IGE) (Martinez-Juarez et al., 2006), suggesting they may persist to an advanced age.
  • Seizures in three patients had begun in childhood or adolescence and in one at 40 years.

  • Hazardous Substances Data Bank. CLONAZEPAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285698.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants; 5PE9FDE8GB / Clonazepam
  •  go-up   go-down


77. Ozen S, Duzova A, Bakkaloglu A, Bilginer Y, Cil BE, Demircin M, Davin JC, Bakkaloğlu M: Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr; 2007 Jan;150(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All entered remission.
  • CONCLUSIONS: The presented single-center experience suggests that CYC induction and corticosteroids followed by MTX is an effective and safe treatment for childhood TA.
  • [MeSH-minor] Administration, Oral. Adolescent. Child. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Magnetic Resonance Angiography. Male. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Takayasu arteritis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188618.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


78. Rowe JM: Optimal management of adults with ALL. Br J Haematol; 2009 Feb;144(4):468-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cure rate of acute lymphoblastic leukaemia (ALL) in adults remains unsatisfactory.
  • The remarkable progress in childhood ALL has not been replicated in adult ALL and approximately two thirds of patients younger than 60 years, and more than 90% of those over 60 years, are expected to succumb to their disease.
  • Over 80% of adults can achieve a complete remission; however, the majority of such patients relapse.
  • Prognostic factors have been more clearly defined, moving cytogenetics and molecular determinants forefront, much like acute myeloid leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Humans. Neoplasm, Residual. Prognosis. Remission Induction. Survival Analysis. Treatment Outcome. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055668.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


79. Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F: Clinical outcome in children with Henoch-Schönlein nephritis. Pediatr Nephrol; 2007 Jan;22(1):64-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Henoch-Schönlein purpura (HSP) is the most common vasculitis in childhood.
  • However, 35% of these patients and 62% of them showed complete remission after 6 months and long-term course.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Nephrol. 2003 May;18(5):471-3 [12736812.001]
  • [Cites] Pediatr Int. 1999 Aug;41(4):353-6 [10453182.001]
  • [Cites] Medicine (Baltimore). 1999 Nov;78(6):395-409 [10575422.001]
  • [Cites] Q J Med. 1972 Jul;41(163):241-58 [4538491.001]
  • [Cites] Medicine (Baltimore). 2001 Sep;80(5):279-90 [11552081.001]
  • [Cites] Clin Nephrol. 2003 Sep;60(3):153-60 [14524577.001]
  • [Cites] Nephrol Dial Transplant. 1997 Nov;12(11):2277-83 [9394311.001]
  • [Cites] Lancet. 1984 Sep 1;2(8401):522 [6147580.001]
  • [Cites] Lancet. 2002 Aug 31;360(9334):666-70 [12241872.001]
  • [Cites] Ann Med Interne (Paris). 1999 Feb;150(2):151-9 [10392264.001]
  • [Cites] Eur J Pediatr. 1988 Feb;147(2):113-5 [3366130.001]
  • [Cites] Arch Dis Child. 2005 Sep;90(9):916-20 [15871983.001]
  • [Cites] Pediatr Nephrol. 1999 Nov;13(9):816-23 [10603128.001]
  • [Cites] J Am Soc Nephrol. 1999 Dec;10(12):2637-44 [10589705.001]
  • [Cites] Clin Nephrol. 2003 Aug;60(2):80-4 [12940608.001]
  • [Cites] Semin Arthritis Rheum. 2005 Dec;35(3):143-53 [16325655.001]
  • [Cites] Arch Dis Child. 1981 Jun;56(6):482-4 [7259283.001]
  • [Cites] Eur J Pediatr. 2001 Dec;160(12):689-95 [11795675.001]
  • [Cites] Pediatr Nephrol. 1995 Feb;9(1):6-10 [7742225.001]
  • [Cites] Trop Geogr Med. 1990 Jan;42(1):52-7 [2260196.001]
  • [Cites] Lancet. 1992 Feb 1;339(8788):280-2 [1346291.001]
  • [Cites] Kidney Int. 1998 Jun;53(6):1755-9 [9607209.001]
  • (PMID = 17024391.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


80. Elbl L, Hrstkova H, Tomaskova I, Michalek J: Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Support Care Cancer; 2006 Feb;14(2):128-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
  • BACKGROUND: The authors conducted a retrospective study to determine whether dexrazoxane (ICRF-187) would reduce late anthracycline-induced cardiotoxicity in patients treated in childhood for hematological malignancy.
  • All patients were in long-term remission of their malignancy.

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Heart Fail. 2002 Jun;4(3):235-42 [12034146.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] Pediatrics. 1992 May;89(5 Pt 1):942-9 [1579408.001]
  • [Cites] Cancer Treat Rev. 1991 Mar;18(1):1-19 [1933909.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Feb;18(1):72-5 [8556375.001]
  • [Cites] JAMA. 1991 Sep 25;266(12 ):1672-7 [1886191.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1677-82 [11896119.001]
  • [Cites] Am J Med. 1977 Feb;62(2):200-8 [835599.001]
  • [Cites] Am J Cardiol. 2001 May 1;87(9):1120-2, A9 [11348617.001]
  • [Cites] Drugs. 1998 Sep;56(3):385-403 [9777314.001]
  • [Cites] Cancer Treat Rev. 1993 Jan;19(1):57-77 [8431927.001]
  • [Cites] Clin Cardiol. 2001 Oct;24(10):663-9 [11594412.001]
  • [Cites] J Cardiol. 1995 Dec;26(6):357-66 [8558414.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] Cancer Treat Rep. 1978 Jun;62(6):873-9 [667861.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):362-72 [8636745.001]
  • [Cites] Curr Med Chem. 2001 Nov;8(13):1649-60 [11562284.001]
  • [Cites] Br Heart J. 1995 Apr;73(4):340-50 [7756067.001]
  • [Cites] Drugs. 2002;62(14):2089-126 [12269857.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):131-9 [10100273.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2895-903 [12065567.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):47-58 [8644988.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1738-43 [7760889.001]
  • [Cites] Med Pediatr Oncol. 1995 Jun;24(6):352-61 [7715541.001]
  • [Cites] Pediatr Hematol Oncol. 1997 May-Jun;14(3):213-22 [9185206.001]
  • [Cites] Curr Med Chem. 1998 Feb;5(1):1-28 [9481032.001]
  • [Cites] Crit Rev Oncol Hematol. 1998 Jan;27(1):53-68 [9548017.001]
  • [Cites] Br Heart J. 1993 Aug;70(2):185-8 [8038032.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):512-5 [9835904.001]
  • [Cites] Pediatr Cardiol. 1999 Jul-Aug;20(4):252-63 [10368449.001]
  • [Cites] Semin Oncol. 1998 Oct;25(5):525-37 [9783592.001]
  • [Cites] Cancer Prev Control. 1999 Apr;3(2):145-59 [10474762.001]
  • (PMID = 16034614.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Cardiovascular Agents; 5AR83PR647 / Razoxane
  •  go-up   go-down


81. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P: Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results. Ann Oncol; 2005 Dec;16(12):1936-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hodgkin's disease (HD) accounts for 7.5% of childhood malignancies in Iran.
  • RESULTS: All patients achieved complete remission (CR).
  • Salvage chemotherapy consisted of MOPP/ABVD hybrid; six patients achieved a second sustained remission and three patients died: two due to relapse and progressive disease and the third one in CR, owing to thrombocytopenic hemorrhage and foudroyant pneumonia.
  • Aside from minor acute toxicities, three patients demonstrated azoospermia at the age of 18 years and one of these patients suffered non-Hodgkin lymphoma as a second malignancy.
  • HD occurred as a second malignancy in two patients with acute lymphoblastic leukemia.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157620.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Donaldson KE, Karp CL, Dunbar MT: Evaluation and treatment of children with ocular rosacea. Cornea; 2007 Jan;26(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Retrospective chart review of 20 patients (age, 22 months to 17 years) who presented during childhood with corneal pathology, lid margin disease, and skin changes consistent with ocular rosacea.
  • The patients maintained remission for up to 4 years after a slow taper of systemic treatment.

  • MedlinePlus Health Information. consumer health - Rosacea.
  • Hazardous Substances Data Bank. Erythromycin .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198012.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 63937KV33D / Erythromycin; N12000U13O / Doxycycline
  •  go-up   go-down


83. Dong L, Pan C, Xue HL, Chen J, Zhou M, Ye QD, Jiang H, Shen SH, Gu LJ, Tang JY: [Clinical report on protocol HL-98 for childhood Hodgkin's Lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2010 May;31(5):305-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical report on protocol HL-98 for childhood Hodgkin's Lymphoma].
  • OBJECTIVE: To improve the long-term prognosis of childhood Hodgkin's lymphoma (HL) by standard treatment protocol HL-98.
  • To Jun 2009, 21 (80.76%) of them kept in complete remission (CR) at 10 to 120 months follow-up (average 36 months, and median 31 months).


84. Alajlan A, Al-Khawajah M, Al-Sheikh O, Al-Saif F, Al-Rasheed S, Al-Hoqail I, Hamadah IR: Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin. J Am Acad Dermatol; 2006 Apr;54(4):652-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin.
  • BACKGROUND: Linear IgA bullous dermatosis of childhood is a rare autoimmune bullous disease that mainly affects preschool-aged children.
  • RESULTS: We describe 7 patients with linear IgA bullous dermatosis of childhood treated with flucloxacillin.
  • In 4 cases, it induced complete remission within 3 to 4 months of starting therapy with no relapses.
  • CONCLUSION: Flucloxacillin may be considered among the first alternative therapies for linear IgA bullous dermatosis of childhood.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546588.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A; 43B2M34G2V / Floxacillin
  •  go-up   go-down


85. Kikuchi A, Maeda M, Hanada R, Okimoto Y, Ishimoto K, Kaneko T, Ikuta K, Tsuchida M, Tokyo Children's Cancer Study Group (TCCSG): Moyamoya syndrome following childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Mar;48(3):268-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Moyamoya syndrome following childhood acute lymphoblastic leukemia.
  • BACKGROUND: Long-term survivors of childhood acute lymphoblastic leukemia (ALL) sometimes suffer from adverse long-term sequelae.
  • We analyzed the incidence, clinical course and prognosis of moyamoya syndrome (MoS) following childhood ALL.
  • None of the patients had central nervous system (CNS) leukemia.
  • [MeSH-major] Cranial Irradiation / adverse effects. Moyamoya Disease / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Cerebral Infarction / etiology. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Disease Susceptibility. Female. Follow-Up Studies. Humans. Incidence. Japan / epidemiology. Male. Prednisolone / administration & dosage. Quality of Life. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16615044.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


86. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood; 2010 Apr 22;115(16):3206-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
  • The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study.
  • Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10(-4)); MRD high risk (MRD-HR) if 10(-3) or more at day 78 and MRD intermediate risk (MRD-IR): others.
  • MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Infant. Kaplan-Meier Estimate. Neoplasm, Residual. Prognosis. Receptors, Antigen, B-Cell. Receptors, Antigen, T-Cell / genetics. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome


87. Cheng YF, Zhang LP, Lu AD, Liu GL, Wang B, Liu CF: [Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):454-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience].
  • OBJECTIVE: To retrospectively analyze the treatment outcomes and side effects of childhood acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) or ATRA + arsenic trioxide (As2O3).
  • The remission rate and side effects were observed. RESULTS:.
  • CONCLUSIONS: ATRA + As2O3 for patients with newly diagnosed childhood APL is a feasible treatment with higher CR rate, less side effects and longer long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035177.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


88. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BA: Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia; 2010 Feb;24(2):355-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.
  • From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies.
  • Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7+/-1.2%, 68.1+/-1.4% and 73.2+/-2.1%, respectively.
  • Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20016527.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / CA 29139; United States / NCI NIH HHS / CA / U10 CA030969-22; United States / NCI NIH HHS / CA / U10 CA029139-22; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA 30969; United States / NCI NIH HHS / CA / U10 CA029139; United States / NCI NIH HHS / CA / U10 CA098543-07; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA030969; United States / NCI NIH HHS / CA / U10 CA098413-07; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS158683; NLM/ PMC4300959
  •  go-up   go-down


89. Takanashi J, Tada H, Barkovich AJ, Saeki N, Kohno Y: Pituitary cysts in childhood evaluated by MR imaging. AJNR Am J Neuroradiol; 2005 Sep;26(8):2144-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary cysts in childhood evaluated by MR imaging.
  • CONCLUSION: The frequency of pituitary cysts on MR imaging in childhood is almost equal to that of Rathke cleft cysts, as assessed in autopsy studies of subjects aged 10 to 29 years.
  • [MeSH-minor] Brain Neoplasms / complications. Child, Preschool. Contrast Media. Female. Glioma / complications. Humans. Hypothalamus. Infant. Male. Neoplasms, Second Primary. Optic Chiasm. Optic Nerve Neoplasms / complications. Remission, Spontaneous. Retrospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155173.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


90. Menon J, Mathews L, Purushothaman KK: Treating leukemia in a resource poor setting. Indian Pediatr; 2008 May;45(5):410-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating leukemia in a resource poor setting.
  • Acute lymphatic leukemia (ALL) is the commonest childhood malignancy in India; most patients have no access to specialized health care.
  • The case records of 79 patients with acute lymphatic leukemia, treated at a Government Medical College in Kerala over 15 years were analyzed.
  • Of the 73 patients who completed treatment, 23 survived (36%) 20 had event-free survival more than 5 years after remission.
  • [MeSH-major] Health Care Rationing. Health Services Accessibility. Precursor Cell Lymphoblastic Leukemia-Lymphoma / economics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515933.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


91. Tao R, Emslie G, Mayes T, Nakonezny P, Kennard B, Hughes C: Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder. J Am Acad Child Adolesc Psychiatry; 2009 Jan;48(1):71-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.
  • OBJECTIVE: : Less than half of youths achieve remission (minimal to no symptoms) after acute antidepressant treatment.
  • Early identification of who will or will not respond to treatment and achieve remission may help clinicians formulate treatment decisions and shorten the time spent on ineffective treatments.
  • In a prospective open-label fluoxetine study, we investigate indicators of acute treatment response and remission.
  • The rate of symptom improvement, however, is a good indicator of acute treatment response.
  • A significant symptom reduction (approximately 50%) by week 4 is needed to achieve remission at the end of acute treatment.
  • CONCLUSIONS: : This study demonstrated that the rate of symptom improvement during early weeks of acute fluoxetine treatment is a good indicator of remission.
  • Treatment approach may be reevaluated and modified as early as week 4 during acute treatment.Clinical trials registration information-Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents.
  • [MeSH-minor] Acute Disease. Adolescent. Child. Female. Humans. Male. Outcome Assessment (Health Care) / statistics & numerical data. Personality Assessment / statistics & numerical data. Prognosis. Psychometrics / statistics & numerical data. ROC Curve. Secondary Prevention. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Major depressive disorder.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Gen Psychiatry. 2000 Jan;57(1):29-36 [10632230.001]
  • [Cites] Psychiatry Res. 1999 Oct 11;91(3):127-39 [10641577.001]
  • [Cites] Clin Ther. 2003 Aug;25(8):2289-304 [14512135.001]
  • [Cites] JAMA. 2004 Aug 18;292(7):807-20 [15315995.001]
  • [Cites] Arch Gen Psychiatry. 1983 Nov;40(11):1228-31 [6639293.001]
  • [Cites] Gen Hosp Psychiatry. 1992 Jul;14(4):230-6 [1505744.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8 [9204677.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):471-81 [9276848.001]
  • [Cites] Biometrics. 1997 Sep;53(3):983-97 [9333350.001]
  • [Cites] Mol Psychiatry. 1998 Nov;3(6):508-11 [9857976.001]
  • [Cites] J Affect Disord. 1999 Aug;54(3):269-76 [10467970.001]
  • [Cites] J Child Psychol Psychiatry. 2005 Jul;46(7):735-54 [15972068.001]
  • [Cites] J Nerv Ment Dis. 2006 Apr;194(4):241-8 [16614544.001]
  • [Cites] Neuropsychopharmacology. 2006 Sep;31(9):1841-53 [16794566.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1427-39 [17135988.001]
  • [Cites] Psychiatry Res. 2007 Jan 15;149(1-3):195-200 [17157390.001]
  • [Cites] CNS Spectr. 2007 Feb;12(2):147-54 [17277715.001]
  • [Cites] JAMA. 2007 Apr 18;297(15):1683-96 [17440145.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):667-86 [17513980.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Nov;22(11):1141-6 [17486678.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1503-26 [18049300.001]
  • [Cites] Am J Psychiatry. 2008 Apr;165(4):459-67 [18281410.001]
  • [Cites] Biol Psychiatry. 2008 Jun 15;63(12):1171-7 [18061147.001]
  • [Cites] Arch Gen Psychiatry. 1986 May;43(5):421-9 [3964020.001]
  • (PMID = 19057412.001).
  • [ISSN] 1527-5418
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00332787
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH039188; United States / NIMH NIH HHS / MH / R01 MH039188-13; United States / NIMH NIH HHS / MH / R01 MH39188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; 01K63SUP8D / Fluoxetine
  • [Other-IDs] NLM/ NIHMS173252; NLM/ PMC2822388
  •  go-up   go-down


92. Rodriguez Martin J, Pretell Mazzini J, Viña Fernandez R, Marti Ciruelos R, Curto de la Mano A: Ewing sarcoma of clavicle in children: report of 5 cases. J Pediatr Hematol Oncol; 2009 Nov;31(11):820-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing sarcoma accounts for about 2% to 3% of childhood tumors and can occur in any bone, but it is most often found in extremities and central axis.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Remission Induction

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801950.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Sinha MD, MacLeod R, Rigby E, Clark AG: Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant; 2006 Jul;21(7):1848-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Severe steroid-dependent nephrotic syndrome (SDNS) is a common type of nephrotic syndrome (NS) observed in childhood.
  • Tacrolimus (TAC) has been prescribed for maintaining remission of NS in patients who have developed treatment resistance or adverse effects with cyclosporin A (CYA) at our institution since 1995.

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nephrol Dial Transplant. 2006 Jul;21(7):1761-3 [16702202.001]
  • (PMID = 16311257.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcineurin Inhibitors; 0 / Immunosuppressive Agents; 0 / Steroids; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


94. Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R: Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol; 2005 Jul;153(1):81-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in young adult survivors of childhood acute lymphoblastic leukaemia.
  • OBJECTIVE: Obesity is frequently reported in patients treated for childhood leukaemia.
  • DESIGN: All patients treated for acute lymphoblastic leukaemia (ALL) before the onset of puberty in the region of western Sweden, between 1973 and 1985, and in first remission, were included.
  • CONCLUSIONS: We found little effect on BMI but an increased percentage of total body fat, especially trunk fat, and a tendency for an unfavourable lipid profile in adult survivors of childhood leukaemia.

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994749.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin; 0 / Lipids
  •  go-up   go-down


95. Limb SL, Brown KC, Wood RA, Wise RA, Eggleston PA, Tonascia J, Hamilton RG, Adkinson NF Jr: Adult asthma severity in individuals with a history of childhood asthma. J Allergy Clin Immunol; 2005 Jan;115(1):61-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult asthma severity in individuals with a history of childhood asthma.
  • BACKGROUND: Childhood asthma can have a range of outcomes in adulthood.
  • OBJECTIVE: To identify clinical features and exposures associated with persistence and severity of childhood asthma in adulthood.
  • METHODS: Eighty-five of 121 subjects previously enrolled in a study of immunotherapy for childhood allergic asthma (age 5-12 years) were re-evaluated with allergy skin testing, spirometry, and interviews about asthma symptoms and medications.
  • These young adults (age 17-30 years; 74% male) all had moderate to severe childhood asthma.
  • RESULTS: Thirteen (15.3%) of 85 adult subjects were in remission despite persistent childhood asthma.
  • Subjects in remission, compared with subjects with intermittent or persistent asthma, had lower total serum IgE in childhood (412 ng/mL vs 1136 ng/mL vs 968 ng/mL; P = .02) and fewer positive allergy skin tests (7 vs 9 vs 10 from panel of 18; P = .02).
  • Subjects in remission also had milder childhood asthma, indicated by lower average daily medication usage scores (1.6 vs 3.5 vs 4.4; P = .005) and lower percentage of days on inhaled corticosteroids (13.7% vs 24.7% vs 40.9%; P = .008).
  • No significant association was found between current asthma severity and childhood immunotherapy ( P = .46).
  • CONCLUSION: The prognosis of childhood allergic asthma in adulthood is largely determined early in life.
  • [MeSH-minor] Administration, Inhalation. Adolescent. Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Hydroxycorticosteroids / therapeutic use. Immunoglobulin E / blood. Leukotriene Antagonists / therapeutic use. Male. Prognosis. Remission Induction. Risk Factors. Severity of Illness Index. Skin Tests

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637548.001).
  • [ISSN] 0091-6749
  • [Journal-full-title] The Journal of allergy and clinical immunology
  • [ISO-abbreviation] J. Allergy Clin. Immunol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5M01RR02719
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Asthmatic Agents; 0 / Hydroxycorticosteroids; 0 / Leukotriene Antagonists; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


96. Pandey P, Ojha BK, Mahapatra AK: Pediatric pituitary adenoma: a series of 42 patients. J Clin Neurosci; 2005 Feb;12(2):124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric pituitary adenoma: a series of 42 patients.
  • Pituitary adenomas are uncommon in childhood.
  • Overall, 67.6% of patients achieved endocrinological remission.
  • Of these, 89% of the children with GH-secreting tumors and 100% of the children with Cushing's disease achieved remission.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749410.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


97. Ziyab AH, Raza A, Karmaus W, Tongue N, Zhang H, Matthews S, Arshad SH, Roberts G: Trends in eczema in the first 18 years of life: results from the Isle of Wight 1989 birth cohort study. Clin Exp Allergy; 2010 Dec;40(12):1776-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Trends in the prevalence of eczema in the course of childhood and adolescence are not clear although often a net remission during childhood is assumed.
  • RESULTS: The period prevalence of eczema from birth to 18 years of age remained relatively constant (11.9-14.2%) with minimal remission.
  • CONCLUSIONS: We found only a minimal reduction in the prevalence of eczema during childhood and adolescence.

  • Genetic Alliance. consumer health - Eczema.
  • MedlinePlus Health Information. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21059120.001).
  • [ISSN] 1365-2222
  • [Journal-full-title] Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • [ISO-abbreviation] Clin. Exp. Allergy
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL082925
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. Hoffenberg EJ: Should all children be screened for celiac disease? Gastroenterology; 2005 Apr;128(4 Suppl 1):S98-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address the issue of screening children for celiac disease, current evidence has been summarized and placed within the context of 8 established criteria for childhood screening.
  • These include the timing of screening, defining the natural history of screening-identified celiac disease, developing tools to predict disease onset and disease remission, and the risks of screening.

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825134.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


99. Muñoz A, Diaz-Heredia C, Diaz MA, Badell I, Verdeguer A, Martinez A, Gomez P, Perez-Hurtado JM, Bureo E, Fernandez-Delgado R, Gonzalez-Valentin ME, Maldonado MS: Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon). Pediatr Hematol Oncol; 2008 Jun;25(4):245-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Infant. Male. Quality of Life. Recurrence. Remission Induction. Survival Rate. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome


100. Brown BJ, Bamgboye EA, Sodeinde O: Causes of death in childhood cancer at the Department of Paediatrics, University College Hospital, Ibadan. Afr J Med Med Sci; 2008 Mar;37(1):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Causes of death in childhood cancer at the Department of Paediatrics, University College Hospital, Ibadan.
  • The objectives of this study were to determine the underlying and immediate causes of death from childhood cancer.
  • The mortality summary cards of all cases of childhood cancer seen at the Department of Paediatrics, University College Hospital, Ibadan between January 1998 and December 2004 were reviewed.
  • Eighty-eight cases of childhood cancer were seen, out of whom 52 (59.1%) died, but only the 48 deaths with complete data were analyzed.
  • Of the 48 cases reviewed, 39 (81.3%) died without any remission of the primary tumour including 5 (10.4%) with disease progression despite treatment and 15 (31.3%) who died before treatment; only 4 cases (8.3%) died from tumour relapse.
  • Potentially reversible factors such as infections, bone marrow suppression and treatment-related events are the commonest causes of death from childhood cancer in Ibadan.
  • Therefore, early presentation, prompt identification and effective management of these problems may reduce childhood cancer mortality in Nigeria.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756849.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down






Advertisement